CA2273071C - Method for ligating oligopeptides - Google Patents
Method for ligating oligopeptides Download PDFInfo
- Publication number
- CA2273071C CA2273071C CA002273071A CA2273071A CA2273071C CA 2273071 C CA2273071 C CA 2273071C CA 002273071 A CA002273071 A CA 002273071A CA 2273071 A CA2273071 A CA 2273071A CA 2273071 C CA2273071 C CA 2273071C
- Authority
- CA
- Canada
- Prior art keywords
- terminal
- oligopeptide
- peptide
- glycine
- terminal residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 80
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 94
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 55
- 150000007970 thio esters Chemical group 0.000 claims description 38
- 239000004471 Glycine Substances 0.000 claims description 32
- 125000000524 functional group Chemical group 0.000 claims description 27
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 21
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 20
- 210000004899 c-terminal region Anatomy 0.000 claims description 18
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 11
- 150000003573 thiols Chemical class 0.000 claims description 11
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 9
- 239000003638 chemical reducing agent Substances 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- -1 N-substituted amide Chemical class 0.000 abstract description 22
- 230000008707 rearrangement Effects 0.000 abstract description 15
- 238000006467 substitution reaction Methods 0.000 abstract description 2
- 125000003368 amide group Chemical group 0.000 abstract 1
- 239000000047 product Substances 0.000 description 42
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000011347 resin Substances 0.000 description 15
- 229920005989 resin Polymers 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 9
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 7
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 238000011894 semi-preparative HPLC Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- OCWDBKQNNKCYCJ-UHFFFAOYSA-N 2-(2-bromoethoxy)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(OCCBr)C(=O)C2=C1 OCWDBKQNNKCYCJ-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- AGFYZLVFPSGUIX-UHFFFAOYSA-N (4-methylphenyl)methanethiol Chemical compound CC1=CC=C(CS)C=C1 AGFYZLVFPSGUIX-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 3
- PTBZDRNYLVWFBA-UHFFFAOYSA-N o-(1-sulfanylethyl)hydroxylamine Chemical class CC(S)ON PTBZDRNYLVWFBA-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000012630 HPLC buffer Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- ZQXIMYREBUZLPM-UHFFFAOYSA-N 1-aminoethanethiol Chemical class CC(N)S ZQXIMYREBUZLPM-UHFFFAOYSA-N 0.000 description 1
- OCWGRWAYARCRTQ-UHFFFAOYSA-N 2-chloro-n,n-dimethylpropan-1-amine;hydron;chloride Chemical compound Cl.CC(Cl)CN(C)C OCWGRWAYARCRTQ-UHFFFAOYSA-N 0.000 description 1
- 108010016529 Bacillus amyloliquefaciens ribonuclease Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 108010031145 eglin proteinase inhibitors Proteins 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QIHOAPIMFMYKJZ-UHFFFAOYSA-N o-[2-[(4-methylphenyl)methylsulfanyl]ethyl]hydroxylamine Chemical compound CC1=CC=C(CSCCON)C=C1 QIHOAPIMFMYKJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005543 phthalimide group Chemical group 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Oligopeptides are ligated to form ligation peptide products. In the first step, two starting oligopeptides are ligated to form an intermediate having an aminothioester linkage. In the second step, the aminothioester linkage undergoes a rearrangement to form a peptide having an N-substituted amide linkage. In an optional third step, the N-substitution of the amide linkage is chemically removed to form a native peptide linkage.
Description
METHOD FOR LIGATING OLIGOPEPTIDES
Descr jpt i on Technical Field of the Invention:
The present invention relates to methods for chemically ligating oligopeptides. More particularly, the invention relates to methods for chemically ligating oligopeptides end to end using a peptide bond.
Government Rights:
This invention was made with government support under Grants No. RO1 GM 48897 and P01 GM 48870 awarded by the National Institutes of Health. The U.S.
government has certain rights in the invention.
Background of the Invention:
The synthesis of peptides by conventional stepwise solid phase methodologies is limited by low yields when synthesizing long peptides. (Merrifield et al. J. Am.
Chem. Soc. 1963, 85, 2149-2154; Kent et al. Ann. Rev.
Biochem. 1988, 57, 957-989.) To overcome this limitation, smaller synthetic peptides may be joined to one another by chemical ligation to produce longer peptide products.
A method for chemically ligating peptides was disclosed by Schnolzer et al.. (Schnolzer et al., Science 1992, 256, 221-225; Rose et al. J. Am. Chem.
Soc. 1994, 116, 30-34; Liu et al. Proc. Natl. Acad. Sci.
USA 1994, 91, 6584-6588). The methodology disclosed by Schnolzer involves a chemoselective reaction of unprotected peptide segments to give a product with an unnatural backbone structure at the site of ligation.
This methodology makes possible the synthesis of peptides of greater size than attainable by standard methods of peptide synthesis. (Canne et al. J. Am. Cheln.
Descr jpt i on Technical Field of the Invention:
The present invention relates to methods for chemically ligating oligopeptides. More particularly, the invention relates to methods for chemically ligating oligopeptides end to end using a peptide bond.
Government Rights:
This invention was made with government support under Grants No. RO1 GM 48897 and P01 GM 48870 awarded by the National Institutes of Health. The U.S.
government has certain rights in the invention.
Background of the Invention:
The synthesis of peptides by conventional stepwise solid phase methodologies is limited by low yields when synthesizing long peptides. (Merrifield et al. J. Am.
Chem. Soc. 1963, 85, 2149-2154; Kent et al. Ann. Rev.
Biochem. 1988, 57, 957-989.) To overcome this limitation, smaller synthetic peptides may be joined to one another by chemical ligation to produce longer peptide products.
A method for chemically ligating peptides was disclosed by Schnolzer et al.. (Schnolzer et al., Science 1992, 256, 221-225; Rose et al. J. Am. Chem.
Soc. 1994, 116, 30-34; Liu et al. Proc. Natl. Acad. Sci.
USA 1994, 91, 6584-6588). The methodology disclosed by Schnolzer involves a chemoselective reaction of unprotected peptide segments to give a product with an unnatural backbone structure at the site of ligation.
This methodology makes possible the synthesis of peptides of greater size than attainable by standard methods of peptide synthesis. (Canne et al. J. Am. Cheln.
Soc. 1995, 117, 2998-3007; Baca et al. J. Am. Chem. Soc.
1995, 117, 1881-1887; Williams et al. J. Am. Chem. Soc.
1994, 116, 10797-10798). This methedology also makes possible the synthesis of peptides of unusual structure and topology. (Dawson et al. J. Am. Chem. Soc. 1993, 115, 7263-7266; Rose et al. J. Am. Chem. Soc. 1994, 116, 30-34; Muir et al. Biochemistry 1994, 33, 7701-7708;
Canne et al. J. Am. Chem. Soc. 1995, 117, 2998-3007).
The combined use of conventional stepwise solid phase peptide synthesis together with chemical ligation enables chemists to routinely make unprotected peptides of up to 60 amino acid residues in good yield and purity. (Schnolzer et al. Int. J. Pept. Protein Res.
1992, 40, 180-193). The combination of these two methodologies may also be employed to achieve a total chemical synthesis of proteins.
Another chemical ligation technique has been reported for the preparation of proteins having a native backbone structure (Dawson et al. Science 1994, 266, 776-779). This mode of chemical ligation is termed "native ligation." In this technique, an unprotected synthetic peptide bearing a C-terminal a-thioester is reacted in a chemoselective manner with an unprotected peptide containing an N-terminal Cys residue. Thiol exchange reaction yields an intial thioester-linked intermediate which spontaneously rearranges to give a native amide bond at the ligation site joining the two peptide segments, in the process regenerating the Cys side chain thiol. This version of native ligation uses chemistry first described by Wieland for reacting amino acids. (Wieland et al. Liebigs Ann. Chem. 1953, 583, 129-149.) As originally described, native ligation is restricted to joining peptide segments at an X-Cys bond.
(Dawson et al. Science 1994, 266, 776-779.) What is needed is a general method for joining a C-terminal a-thioester peptide segment to an N-terminal amino acid peptide segment, wherein the N-terminal amino acid peptide segment need not have an N-terminal cysteine.
Summary of the Invention:
According to one aspect of the present invention, there is provided a method for ligating a first oligopeptide with a second oligopeptide end to end for producing an oligopeptide product, the method comprising the following steps: Step A: admixing the first and second oligopeptides in a reaction solution including a catalytic thiol, the first oligopeptide including a C-terminal residue having a C-terminal thioester, the second oligopeptide including an N-terminal residue having an N-terminal auxiliary functional group with an unoxidized sulfhydryl moiety, the N-terminal residue being non-glycine and non-cysteine if the C-terminal residue is glycine, the N-terminal residue being glycine if the C-terminal residue is non-glycine; Step B: condensing the unoxidized sulfhydryl moiety of the N-terminal auxiliary functional group with the C-terminal thioester for producing an intermediate oligopeptide linking the first and second oligopeptides with an aminothioester bond; and then Step C: rearranging the aminothioester bond of the intermediate oligopeptide of said Step B for producing the oligopeptide product linking the first and second oligopeptides with an amide bond having a N-linked auxiliary functional group.
According to another aspect of the present invention, there is provided an oligopeptide intermediate comprising: a first oligopeptide segment including a C-terminal residue having a C-terminal thioester, a second - 3a -oligopeptide segment including a N-terminal residue having a N-terminal auxiliary functional group having an unoxidized sulfhydryl moiety, the N-terminal residue being non-glycine and non-cysteine if the C-terminal residue is glycine, the N-terminal residue being glycine if the C-terminal residue is non-glycine, and an aminothioester linkage unit linking the C-terminal thioester and the sulfhydryl moiety of the N-terminal auxiliary functional group, said aminothioester linkage unit spontaneously rearranging intramolecularly to form an amide bond linking said first and second oligopeptides segments end to end.
According to still another aspect of the present invention, there is provided a peptide comprising a linkage unit represented by the formula: (aal-CO) -S- (CH2) n-X- (N-aa2) , wherein aa1-CO is a first amino acid having a carbonyl group, N-aa2 is a second amino acid having an amino group, wherein X is selected from the group consisting of oxygen and methylene, and wherein 1-n-<2.
The invention is directed to a method for chemically ligating unprotected oligopeptides to form a product having all peptide linkages. In the first step, two oligopeptides are ligated to form a ligation product having an aminothioester linkage. In the second step, the aminothioester linkage rearranges to form a product having an N-substituted amide linkage. In an optional third step, the substitution on the amide bond is removed by facile treatment with Zn in acidic medium, to give a native peptide bond at the ligation site.
The method employs two starting oligopeptides, viz., a first starting oligopeptide and a second starting oligopeptide. The first oligopeptide has a C-terminal auxiliary group with a thioester moiety, - 3b -i.e., [peptidel]aCOSR, where R is selected from the group consisting of 3-carboxy 4-nitrophenyl and benzyl. The second oligopeptide has an N-terminal auxiliary functional group with an unoxidized sulfhydryl moiety, i.e., HSCH2CH2(0)-Na[peptide2]. When the first and second starting oligopeptides are admixed under conditions promoting thioester exchange, they condense with one another to form an intermediate oligopeptide product wherein the first and second oligopeptides are linked via an amino-thioester bond. The amino-thioester bond then spontaneously rearranges intramolecularly to form a ligation product linked by an N-substituted amide bond. During the intramolecular rearrangement, the amino group of the N-terminal auxiliary functional group attacks the thioester to form an amide bond with the attached N-linked auxiliary functional group containing a displaced sulfhydryl moiety. The N-linked auxiliary functional group containing the displaced sulfhydryl moiety may then be optionally removed by chemical means to form a product having all native peptide linkages.
One aspect of the invention is directed to a method for ligating a first oligopeptide with a second oligopeptide end to end for producing an oligopeptide product. More particularly, the method comprises two steps with an optional third step.
The first step involves condensing the C-terminal thioester of a first peptide with the unoxidized sulfhydryl moiety of a second oligopeptide for producing an intermediate oligopeptide linking the first and second oligopeptides with an b or Y- amino-thioester bond. The first oligopeptide includes the C-terminal thioester on a C-terminal residue and the second oligopeptide includes the N-terminal auxiliary functional group on an N-terminal residue having an unoxidized sulfhydryl moiety. If the C-terminal residue on the first oligopeptide is non glycine then the N-terminal residue on the second oligopeptide is glycine and if the N-terminal residue on the second oligopeptide is non glycine then the C-terminal residue on the first oligopeptide is glycine with the proviso that the non glycine residue is a non R-branched amino acid.
The second step rearranges the 5 or Y- amino-thioester bond of the intermediate oligopeptide via intramolecular attack of the b or y - amino group onto the thioester moiety and displaces a sulfhydryl moiety as a byproduct from the thioester moiety thereby producing an oligopeptide product linking the first and second oligopeptides with an amide bond. The nitrogen of the amide bond contains the auxiliary functional group with the displaced sulfhydryl moiety.
An optional third step involves the removal of the auxiliary functional group on the amide nitrogen, from the oligopeptide product with a reducing agent for producing a native peptide bond. The amide nitrogen auxiliary functional group is N-a-O-(CH2),-SH wherein 1sns2 and the reducing agent is Zinc (underlined nitrogen represents the coupled amide nitrogen).
Another apect of the invention includes the oligopeptide intermediate comprising a first oligopeptide segment including a C-terminal thioester, a second oligopeptide segment including an N-terminal auxiliary functional group having an unoxidized sulfhydryl moiety, and an aminothioester linkage unit linking the C-terminal thioester and the sulfhydryl group of the auxiliary functional group.
Description of Figures:
Figure 1 illustrates the generalized native chemical ligation of unprotected peptide segments wherein R is a non R-branched amino acid residue with the following conditions: if the C-terminal residue on the first oligopeptide is non glycine then the N-terminal residue on the second oligopeptide is glycine and if the N-terminal residue on the second oligopeptide is non glycine then the C-terminal residue on the first oligopeptide is glycine. RI is selected from the group consisting of 3-carboxy 4-nitrophenyl and benzyl.
Figure 2 illustrates the chemical synthesis of N(substituted) peptide segments 2a and 2b.
Figure 3 illustrates the chemical synthesis of compound 8b.
1995, 117, 1881-1887; Williams et al. J. Am. Chem. Soc.
1994, 116, 10797-10798). This methedology also makes possible the synthesis of peptides of unusual structure and topology. (Dawson et al. J. Am. Chem. Soc. 1993, 115, 7263-7266; Rose et al. J. Am. Chem. Soc. 1994, 116, 30-34; Muir et al. Biochemistry 1994, 33, 7701-7708;
Canne et al. J. Am. Chem. Soc. 1995, 117, 2998-3007).
The combined use of conventional stepwise solid phase peptide synthesis together with chemical ligation enables chemists to routinely make unprotected peptides of up to 60 amino acid residues in good yield and purity. (Schnolzer et al. Int. J. Pept. Protein Res.
1992, 40, 180-193). The combination of these two methodologies may also be employed to achieve a total chemical synthesis of proteins.
Another chemical ligation technique has been reported for the preparation of proteins having a native backbone structure (Dawson et al. Science 1994, 266, 776-779). This mode of chemical ligation is termed "native ligation." In this technique, an unprotected synthetic peptide bearing a C-terminal a-thioester is reacted in a chemoselective manner with an unprotected peptide containing an N-terminal Cys residue. Thiol exchange reaction yields an intial thioester-linked intermediate which spontaneously rearranges to give a native amide bond at the ligation site joining the two peptide segments, in the process regenerating the Cys side chain thiol. This version of native ligation uses chemistry first described by Wieland for reacting amino acids. (Wieland et al. Liebigs Ann. Chem. 1953, 583, 129-149.) As originally described, native ligation is restricted to joining peptide segments at an X-Cys bond.
(Dawson et al. Science 1994, 266, 776-779.) What is needed is a general method for joining a C-terminal a-thioester peptide segment to an N-terminal amino acid peptide segment, wherein the N-terminal amino acid peptide segment need not have an N-terminal cysteine.
Summary of the Invention:
According to one aspect of the present invention, there is provided a method for ligating a first oligopeptide with a second oligopeptide end to end for producing an oligopeptide product, the method comprising the following steps: Step A: admixing the first and second oligopeptides in a reaction solution including a catalytic thiol, the first oligopeptide including a C-terminal residue having a C-terminal thioester, the second oligopeptide including an N-terminal residue having an N-terminal auxiliary functional group with an unoxidized sulfhydryl moiety, the N-terminal residue being non-glycine and non-cysteine if the C-terminal residue is glycine, the N-terminal residue being glycine if the C-terminal residue is non-glycine; Step B: condensing the unoxidized sulfhydryl moiety of the N-terminal auxiliary functional group with the C-terminal thioester for producing an intermediate oligopeptide linking the first and second oligopeptides with an aminothioester bond; and then Step C: rearranging the aminothioester bond of the intermediate oligopeptide of said Step B for producing the oligopeptide product linking the first and second oligopeptides with an amide bond having a N-linked auxiliary functional group.
According to another aspect of the present invention, there is provided an oligopeptide intermediate comprising: a first oligopeptide segment including a C-terminal residue having a C-terminal thioester, a second - 3a -oligopeptide segment including a N-terminal residue having a N-terminal auxiliary functional group having an unoxidized sulfhydryl moiety, the N-terminal residue being non-glycine and non-cysteine if the C-terminal residue is glycine, the N-terminal residue being glycine if the C-terminal residue is non-glycine, and an aminothioester linkage unit linking the C-terminal thioester and the sulfhydryl moiety of the N-terminal auxiliary functional group, said aminothioester linkage unit spontaneously rearranging intramolecularly to form an amide bond linking said first and second oligopeptides segments end to end.
According to still another aspect of the present invention, there is provided a peptide comprising a linkage unit represented by the formula: (aal-CO) -S- (CH2) n-X- (N-aa2) , wherein aa1-CO is a first amino acid having a carbonyl group, N-aa2 is a second amino acid having an amino group, wherein X is selected from the group consisting of oxygen and methylene, and wherein 1-n-<2.
The invention is directed to a method for chemically ligating unprotected oligopeptides to form a product having all peptide linkages. In the first step, two oligopeptides are ligated to form a ligation product having an aminothioester linkage. In the second step, the aminothioester linkage rearranges to form a product having an N-substituted amide linkage. In an optional third step, the substitution on the amide bond is removed by facile treatment with Zn in acidic medium, to give a native peptide bond at the ligation site.
The method employs two starting oligopeptides, viz., a first starting oligopeptide and a second starting oligopeptide. The first oligopeptide has a C-terminal auxiliary group with a thioester moiety, - 3b -i.e., [peptidel]aCOSR, where R is selected from the group consisting of 3-carboxy 4-nitrophenyl and benzyl. The second oligopeptide has an N-terminal auxiliary functional group with an unoxidized sulfhydryl moiety, i.e., HSCH2CH2(0)-Na[peptide2]. When the first and second starting oligopeptides are admixed under conditions promoting thioester exchange, they condense with one another to form an intermediate oligopeptide product wherein the first and second oligopeptides are linked via an amino-thioester bond. The amino-thioester bond then spontaneously rearranges intramolecularly to form a ligation product linked by an N-substituted amide bond. During the intramolecular rearrangement, the amino group of the N-terminal auxiliary functional group attacks the thioester to form an amide bond with the attached N-linked auxiliary functional group containing a displaced sulfhydryl moiety. The N-linked auxiliary functional group containing the displaced sulfhydryl moiety may then be optionally removed by chemical means to form a product having all native peptide linkages.
One aspect of the invention is directed to a method for ligating a first oligopeptide with a second oligopeptide end to end for producing an oligopeptide product. More particularly, the method comprises two steps with an optional third step.
The first step involves condensing the C-terminal thioester of a first peptide with the unoxidized sulfhydryl moiety of a second oligopeptide for producing an intermediate oligopeptide linking the first and second oligopeptides with an b or Y- amino-thioester bond. The first oligopeptide includes the C-terminal thioester on a C-terminal residue and the second oligopeptide includes the N-terminal auxiliary functional group on an N-terminal residue having an unoxidized sulfhydryl moiety. If the C-terminal residue on the first oligopeptide is non glycine then the N-terminal residue on the second oligopeptide is glycine and if the N-terminal residue on the second oligopeptide is non glycine then the C-terminal residue on the first oligopeptide is glycine with the proviso that the non glycine residue is a non R-branched amino acid.
The second step rearranges the 5 or Y- amino-thioester bond of the intermediate oligopeptide via intramolecular attack of the b or y - amino group onto the thioester moiety and displaces a sulfhydryl moiety as a byproduct from the thioester moiety thereby producing an oligopeptide product linking the first and second oligopeptides with an amide bond. The nitrogen of the amide bond contains the auxiliary functional group with the displaced sulfhydryl moiety.
An optional third step involves the removal of the auxiliary functional group on the amide nitrogen, from the oligopeptide product with a reducing agent for producing a native peptide bond. The amide nitrogen auxiliary functional group is N-a-O-(CH2),-SH wherein 1sns2 and the reducing agent is Zinc (underlined nitrogen represents the coupled amide nitrogen).
Another apect of the invention includes the oligopeptide intermediate comprising a first oligopeptide segment including a C-terminal thioester, a second oligopeptide segment including an N-terminal auxiliary functional group having an unoxidized sulfhydryl moiety, and an aminothioester linkage unit linking the C-terminal thioester and the sulfhydryl group of the auxiliary functional group.
Description of Figures:
Figure 1 illustrates the generalized native chemical ligation of unprotected peptide segments wherein R is a non R-branched amino acid residue with the following conditions: if the C-terminal residue on the first oligopeptide is non glycine then the N-terminal residue on the second oligopeptide is glycine and if the N-terminal residue on the second oligopeptide is non glycine then the C-terminal residue on the first oligopeptide is glycine. RI is selected from the group consisting of 3-carboxy 4-nitrophenyl and benzyl.
Figure 2 illustrates the chemical synthesis of N(substituted) peptide segments 2a and 2b.
Figure 3 illustrates the chemical synthesis of compound 8b.
Figure 4 shows a table with summaries of model ligations for Examples #1-5. Superscript is as follows:
(a) Thioester peptides where -SNB=3-carboxy-4-nitrophenyl thioester arid -Sbzl = benzyl thioester; (b) N (substituted) peptides where etsh=N '(ethanethiol)- and oetsh=N '(oxyethanethiol)-; (c) Based on Peptide 2, estimated from analytical reverse phase HPLC (peak areas) and ESMS; (d) Adjusted to pH 4.5 after the indicated hrs at pH 7.5.
Figures 5A-5C illustrate the model ligation,-_Example #2 ( infra) , to form amide -Gly (N '-OCH2CH2SH) Gly- compound 4b carried out in 6 M guanidine=HC1, 0.1 M NaZHPO4i pH
(a) Thioester peptides where -SNB=3-carboxy-4-nitrophenyl thioester arid -Sbzl = benzyl thioester; (b) N (substituted) peptides where etsh=N '(ethanethiol)- and oetsh=N '(oxyethanethiol)-; (c) Based on Peptide 2, estimated from analytical reverse phase HPLC (peak areas) and ESMS; (d) Adjusted to pH 4.5 after the indicated hrs at pH 7.5.
Figures 5A-5C illustrate the model ligation,-_Example #2 ( infra) , to form amide -Gly (N '-OCH2CH2SH) Gly- compound 4b carried out in 6 M guanidine=HC1, 0.1 M NaZHPO4i pH
7.5. (A)-(C) represent HPLC plots as follows: (A) Analytical HPLC (10-50%B over 30 min) at t = 0; peak a thioester peptide, 1, LYRAQ= COSC6H3 (3-COZH-4-N02) ; peak b, N '(oxyethanethiol) peptide, 2b, [HSCH2CH2O]-gRNTATIMMQRGNFR- 'CONH2i (B) Analytical HPLC (10-50%B
over 30 min) at t = 1 h; peak c, non-peptide impurity;
peak d, LYRAG- 'COSC6H5, resulting from transthioesterification of 1(peak a) with thiophenol;
peak e, intermediate ligation product, 4b, LYRAaG(N '-OCH2CH2SH)RNTATIMMQRGNFR- CONH2 and a minor amount of unreacted [HSCH2CHZO] -_QRNTATIMMQRGNFR-"CONH2 (2b), as determined by electrospray ionization MS. (C) Analytical I-IPLC (15-40%B over 30 min) of peak e after HPLC-purification and treatment with Zn in acidic HPLC
solvent overnight; peak f, final ligation product, 5b, LYRAZ2RNTATIMMQRGNFR- 'CONH2i peak g, non-peptide impurity.
Figures 6A-6C illustrate the model ligation, Example #3 (infra) to form a -Phe(N -OCH2CH2SH) Gly- linked product 4b. Ligation and rearrangement carried out at 37 C. (A)-(C) represent HPLC plots as follows: (A) Analytical HPLC (20-40%B over 30 min) after 11.5 h in 6 M guanidine=HC1, 0.1 M NaZHPO41 pH 7.5; peak a, SUBSTITUTE SHEET (RULE 26) N"(oxyethanethiol) peptide, 2b, [HSCH2CH2O]--QRNTATIMMQRGNFR- 'CONH2i peak b, unrearranged intermediate ligation product, 3b, LYRAE- [ 'COSCH2CH2O J-CzRNTATIMMQRGNFR-"CONH2i peak c, rearranged intermediate ligation product, 4b, LYRAFS (N '-OCH2CH2SH) RNTATIMMQRGNFR-'CONH2i peak d, thioester peptide, 1, LYRAE-"COSCH2C6H5.
(B) Analytical HPLC (20-40%B over 30 min) after 10 h in 6 M guanidine*HC1, 0.1 M NaCH3CO2r pH 4.5. (C) Analytical HPLC (0-67%B over 30 min) of HPLC-purified peak c after treatment with Zn in acidic HPLC solvent overnight; peak f, final ligation product, 5b, LYRAZ'zRNTATIMMQRGNFR- 'CONH2 .
Detailed Description of the Invention The invention is directed to a two step method for chemically ligating together two seperate peptide fragments. More particularly, the invention relates to a general methodology for native (amide-forming) chemical ligation of unprotected peptide segments to produce a native peptide bond.
Step 1 comprises the condensation of a C-terminal thioester of a first peptide with an unoxidized sulfhydryl moiety of a second oligopeptide and produces an intermediate oligopeptide which links the first and second oligopeptides with an b or y - amino-thioester bond. If the C-terminal residue on the first oligopeptide is non glycine then the N-terminal residue on the second oligopeptide is glycine and if the N-terminal residue on the second oligopeptide is non glycine then the C-terminal residue on the first oligopeptide is glycine with the proviso that the non glycine residue is a non 0-branched amino acid.
Step 2 comprises the rearrangement of the b or y-amino-thioester bond of the intermediate oligopeptide via intramolecular attack of the 5 or y - amino group onto the thioester moiety which displaces a sulfhydryl moiety as a byproduct from the thioester moiety and produces an oligopeptide product linking the first and second oligopeptides with a native amide bond. The nitrogen of the amide bond, however, contains the auxiliary functional group with the displaced sulfhydryl moiety.
An optional third step comprises the removal of the auxiliary functional group on the amide nitrogen, from the oligopeptide product with a reducing agent and produces a native peptide bond. The amide nitrogen auxiliary functional group is N-a-O-(CH2)N-SH wherein 1_<n_2 and the reducing agent is Zinc (underlined nitrogen represents the coupled amide nitrogen).
The method allows for the synthesis of peptides and proteins with either native or modified backbone structures. Figure 1 outlines the procedure. The peptide a-carboxythioester (1) reacts, via thiol exchange, with either an N"(ethanethiol) peptide (2a) or an N (oxyethanethiol) peptide (2b) to produce the ligation product 3. This thioester-linked intermediate rearranges through a favorable geometric arrangement involving a 5- or 6-membered ring to give the amide-linked product 4, containing a secondary amide in 4a or the analogous N-oxyalkyl compound in 4b. The resulting N- '(substituted)amides also have potentially favorable solubility properties (Quibell et al. J. Am. Chem. Soc.
1995, 117, 11656-11668) the N- (O-alkyl)amide ligation product has the further advantage of being stable to HF
cleavage conditions, yet is simply removed under mild conditions. In the case of 4b, zinc dust can be added directly to the reverse phase HPLC-purified peptide in the acidic eluant to reduce the N-O bond of the 0-alkoxyhydroxamate and give the native backbone structure of ligation product 5b.
over 30 min) at t = 1 h; peak c, non-peptide impurity;
peak d, LYRAG- 'COSC6H5, resulting from transthioesterification of 1(peak a) with thiophenol;
peak e, intermediate ligation product, 4b, LYRAaG(N '-OCH2CH2SH)RNTATIMMQRGNFR- CONH2 and a minor amount of unreacted [HSCH2CHZO] -_QRNTATIMMQRGNFR-"CONH2 (2b), as determined by electrospray ionization MS. (C) Analytical I-IPLC (15-40%B over 30 min) of peak e after HPLC-purification and treatment with Zn in acidic HPLC
solvent overnight; peak f, final ligation product, 5b, LYRAZ2RNTATIMMQRGNFR- 'CONH2i peak g, non-peptide impurity.
Figures 6A-6C illustrate the model ligation, Example #3 (infra) to form a -Phe(N -OCH2CH2SH) Gly- linked product 4b. Ligation and rearrangement carried out at 37 C. (A)-(C) represent HPLC plots as follows: (A) Analytical HPLC (20-40%B over 30 min) after 11.5 h in 6 M guanidine=HC1, 0.1 M NaZHPO41 pH 7.5; peak a, SUBSTITUTE SHEET (RULE 26) N"(oxyethanethiol) peptide, 2b, [HSCH2CH2O]--QRNTATIMMQRGNFR- 'CONH2i peak b, unrearranged intermediate ligation product, 3b, LYRAE- [ 'COSCH2CH2O J-CzRNTATIMMQRGNFR-"CONH2i peak c, rearranged intermediate ligation product, 4b, LYRAFS (N '-OCH2CH2SH) RNTATIMMQRGNFR-'CONH2i peak d, thioester peptide, 1, LYRAE-"COSCH2C6H5.
(B) Analytical HPLC (20-40%B over 30 min) after 10 h in 6 M guanidine*HC1, 0.1 M NaCH3CO2r pH 4.5. (C) Analytical HPLC (0-67%B over 30 min) of HPLC-purified peak c after treatment with Zn in acidic HPLC solvent overnight; peak f, final ligation product, 5b, LYRAZ'zRNTATIMMQRGNFR- 'CONH2 .
Detailed Description of the Invention The invention is directed to a two step method for chemically ligating together two seperate peptide fragments. More particularly, the invention relates to a general methodology for native (amide-forming) chemical ligation of unprotected peptide segments to produce a native peptide bond.
Step 1 comprises the condensation of a C-terminal thioester of a first peptide with an unoxidized sulfhydryl moiety of a second oligopeptide and produces an intermediate oligopeptide which links the first and second oligopeptides with an b or y - amino-thioester bond. If the C-terminal residue on the first oligopeptide is non glycine then the N-terminal residue on the second oligopeptide is glycine and if the N-terminal residue on the second oligopeptide is non glycine then the C-terminal residue on the first oligopeptide is glycine with the proviso that the non glycine residue is a non 0-branched amino acid.
Step 2 comprises the rearrangement of the b or y-amino-thioester bond of the intermediate oligopeptide via intramolecular attack of the 5 or y - amino group onto the thioester moiety which displaces a sulfhydryl moiety as a byproduct from the thioester moiety and produces an oligopeptide product linking the first and second oligopeptides with a native amide bond. The nitrogen of the amide bond, however, contains the auxiliary functional group with the displaced sulfhydryl moiety.
An optional third step comprises the removal of the auxiliary functional group on the amide nitrogen, from the oligopeptide product with a reducing agent and produces a native peptide bond. The amide nitrogen auxiliary functional group is N-a-O-(CH2)N-SH wherein 1_<n_2 and the reducing agent is Zinc (underlined nitrogen represents the coupled amide nitrogen).
The method allows for the synthesis of peptides and proteins with either native or modified backbone structures. Figure 1 outlines the procedure. The peptide a-carboxythioester (1) reacts, via thiol exchange, with either an N"(ethanethiol) peptide (2a) or an N (oxyethanethiol) peptide (2b) to produce the ligation product 3. This thioester-linked intermediate rearranges through a favorable geometric arrangement involving a 5- or 6-membered ring to give the amide-linked product 4, containing a secondary amide in 4a or the analogous N-oxyalkyl compound in 4b. The resulting N- '(substituted)amides also have potentially favorable solubility properties (Quibell et al. J. Am. Chem. Soc.
1995, 117, 11656-11668) the N- (O-alkyl)amide ligation product has the further advantage of being stable to HF
cleavage conditions, yet is simply removed under mild conditions. In the case of 4b, zinc dust can be added directly to the reverse phase HPLC-purified peptide in the acidic eluant to reduce the N-O bond of the 0-alkoxyhydroxamate and give the native backbone structure of ligation product 5b.
All peptide segments were synthesized in stepwise fashion by established solid phase methods using in situ neutralization/2-(1H-benzotriazol-l-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) activati.on protocols for tert-butoxycarbonyl (Boc) chemistry, purified by preparative reverse phase HPLC, and characterized by electrospray mass spectrometry (ESMS) (Schndlzer et al. Int. J. Pept. Protein Res. 1992, 40, 180-193). Peptide-a-thioesters (1) were generated from the corresponding peptide-a-thioacids, which in turn, were synthesized on a thioester resin as described in Canne et al. Tetrahedron Lett. 1995, 36, 1217-1220).
The peptide-a-thioacids were converted to either the corresponding 3-carboxy-4-nitrophenyl thioesters in 6 M
guanidine=HC1, 0.1 M Na acetate, pH 5.0-6.5, by reaction with 1.5 equivalents of 5,51-dithio-bis(2-nitrobenzoic acid) or to the corresponding benzyl ester in 6M
guanidine=HC1, 0.1 M Na acetate, pH 4.0, using 10 equivalents of benzyl bromide (Dawson et al. Science 1994, 266, 776-779). Both these thioesters provide satisfactory leaving groups for the ligation reactions, with the 3-carboxy-4-nitrophenyl thioesters demonstrating a somewhat faster reaction rate than the corresponding benzyl thioesters (Dawson et al. Science 1994, 266, 776-779).
The syntheses of N"(ethanethiol)- (2a) and N '(oxyethanethiol)- peptides (2b) are illustrated in Figure 2. The appropriate a-bromocarboxylic acid, activated as the symmetric anhydride (0.5 equivalents 1,3-diisopropylcarbodiimde (DIC) in dichloromethane) (Robey et al. Anal. Biochem. 1989, 177, 373-377) was coupled to the deprotected N-terminal amino acid of peptide-resin 6 to give bromoacyl-peptide-resin 7. The bromide was then displaced, with inversion of stereochemistry, by the amine function of either structure 8a or 8b in DMSO to give peptide-resin 9.
The peptide-a-thioacids were converted to either the corresponding 3-carboxy-4-nitrophenyl thioesters in 6 M
guanidine=HC1, 0.1 M Na acetate, pH 5.0-6.5, by reaction with 1.5 equivalents of 5,51-dithio-bis(2-nitrobenzoic acid) or to the corresponding benzyl ester in 6M
guanidine=HC1, 0.1 M Na acetate, pH 4.0, using 10 equivalents of benzyl bromide (Dawson et al. Science 1994, 266, 776-779). Both these thioesters provide satisfactory leaving groups for the ligation reactions, with the 3-carboxy-4-nitrophenyl thioesters demonstrating a somewhat faster reaction rate than the corresponding benzyl thioesters (Dawson et al. Science 1994, 266, 776-779).
The syntheses of N"(ethanethiol)- (2a) and N '(oxyethanethiol)- peptides (2b) are illustrated in Figure 2. The appropriate a-bromocarboxylic acid, activated as the symmetric anhydride (0.5 equivalents 1,3-diisopropylcarbodiimde (DIC) in dichloromethane) (Robey et al. Anal. Biochem. 1989, 177, 373-377) was coupled to the deprotected N-terminal amino acid of peptide-resin 6 to give bromoacyl-peptide-resin 7. The bromide was then displaced, with inversion of stereochemistry, by the amine function of either structure 8a or 8b in DMSO to give peptide-resin 9.
Deprotection and cleavage from the resin in anhydrous HF
gave 2b directly or 2a still in the form of the disulfide which was reduced to the free thiol.
The aminoethanethiol derivative 8a was synthesized in one step from the reaction of 2-aminoethanethiol and 5,5'-dithio-bis(2-nitrobenzoic acid) in 80% acetonitrile in water. The synthesis of the aminooxyethanethiol derivative 8b was more involved and is illustrated in Figure 3. Bromide 11 was produced from the reaction of N-hydroxyphthalimide (10) with a large excess of 1,2-dibromoethane (Bauer J. Org. Chem. 1963, 28, 1604-1608).
Bromide 11 was then converted to the protected aminooxyethanethiol derivative 12 with 4-methylbenzyl mercaptan in the presence of the base 1,8-Diazabicylco[5.4.0]undeC-7-ene (DBU). The phthalimide group of 12 was removed in a two step process (Osby et al. Tetrahedron Lett. 1984, 25, 2093-2096) involving reduction with NaBH4 followed by treatment with acetic acid to give the desired aminooxyethanethiol derivative 8b.
Compared with the original native chemical ligation at X-Cys sites (Dawson et al. Science 1994, 266, 776-779), the most notable feature of the ligation chemistry of this invention is the slower rearrangement of the initial thioester ligation product. Intramolecular attack by the a-NH(O-alkyl) group via a six-membered ring intermediate in the current instance is considerably less favored (Mandolini et al. J. Am. Chem.
Soc. 1978, 100, 550-554) than the facile five-membered ring mediated attack of the unsubstituted a-NH2 group in the X-Cys ligation (Dawson et al. Science 1994, 266, 776-779).. Except for the Gly-Gly ligation, one is able to isolate the thioester-linked initial ligation product of the present invention (Figure 4), which rearranged only'slowly. Remarkably, for C '-substituted amino acids on both sides of the ligation site, one is unable to observe susbsequent rearrangement to an amide bond: the thioester-linked intermediate was indefinitely stable under the conditions of reaction. These slow rearrangements are similar to those observed in an (N-substituted)amide-forming ligation chemistry previously described (Liu et al. Proc. Nati. Acad. Sci. USA 1994, 91, 6584-6588).
The use, in the invention, of a temporary auxillary functional group in amide-forming ligation is reminiscent of the 'thiol capture' strategy proposed by Kemp (Fotouhi et al. J. Org. Chem. 1989, 54, 2806-2817). Both native chemical ligation and the thiol-capture method have as their stated goal the use of unprotected peptides in a segment condensation strategy to achieve the synthesis of long polypeptide chains.
The key aspect of the native chemical ligation approach is reaction under conditions that promote exchange of the thiol moiety of the initial thioester-linked intermediate products, to give regioselective ligation at the N-terminal Cys even in the presence of other Cys residues in both segments (Dawson et al. Science 1994, 266, 776-779). By contrast, in the 'thiol capture' strategy and related methods (Liu et al. Tetrahedron Lett. 1996, 37, 933-936) regiospecific protection of Cys side chain functionalities prior to the ligation reaction is a necessity (Kemp et al. Peptides:
Proceedings of the 11th American Peptide Symposium Rivier, J.E.; Marshall, G.R., Eds, ESCOM: Lieden, 1990;
pp 920-922), thus frustrating their original intent.
Similarly, the use, in the current invention, of a carbonyl-activated a-thiocarboxyl function (i.e. an a-COSR) is reminiscent of chemistry previously used in peptide segment condensation (Blake et al. Proc. Nati.
Acad. Sci. USA 1981, 78, 4055-4058; Yamashiro et al.
gave 2b directly or 2a still in the form of the disulfide which was reduced to the free thiol.
The aminoethanethiol derivative 8a was synthesized in one step from the reaction of 2-aminoethanethiol and 5,5'-dithio-bis(2-nitrobenzoic acid) in 80% acetonitrile in water. The synthesis of the aminooxyethanethiol derivative 8b was more involved and is illustrated in Figure 3. Bromide 11 was produced from the reaction of N-hydroxyphthalimide (10) with a large excess of 1,2-dibromoethane (Bauer J. Org. Chem. 1963, 28, 1604-1608).
Bromide 11 was then converted to the protected aminooxyethanethiol derivative 12 with 4-methylbenzyl mercaptan in the presence of the base 1,8-Diazabicylco[5.4.0]undeC-7-ene (DBU). The phthalimide group of 12 was removed in a two step process (Osby et al. Tetrahedron Lett. 1984, 25, 2093-2096) involving reduction with NaBH4 followed by treatment with acetic acid to give the desired aminooxyethanethiol derivative 8b.
Compared with the original native chemical ligation at X-Cys sites (Dawson et al. Science 1994, 266, 776-779), the most notable feature of the ligation chemistry of this invention is the slower rearrangement of the initial thioester ligation product. Intramolecular attack by the a-NH(O-alkyl) group via a six-membered ring intermediate in the current instance is considerably less favored (Mandolini et al. J. Am. Chem.
Soc. 1978, 100, 550-554) than the facile five-membered ring mediated attack of the unsubstituted a-NH2 group in the X-Cys ligation (Dawson et al. Science 1994, 266, 776-779).. Except for the Gly-Gly ligation, one is able to isolate the thioester-linked initial ligation product of the present invention (Figure 4), which rearranged only'slowly. Remarkably, for C '-substituted amino acids on both sides of the ligation site, one is unable to observe susbsequent rearrangement to an amide bond: the thioester-linked intermediate was indefinitely stable under the conditions of reaction. These slow rearrangements are similar to those observed in an (N-substituted)amide-forming ligation chemistry previously described (Liu et al. Proc. Nati. Acad. Sci. USA 1994, 91, 6584-6588).
The use, in the invention, of a temporary auxillary functional group in amide-forming ligation is reminiscent of the 'thiol capture' strategy proposed by Kemp (Fotouhi et al. J. Org. Chem. 1989, 54, 2806-2817). Both native chemical ligation and the thiol-capture method have as their stated goal the use of unprotected peptides in a segment condensation strategy to achieve the synthesis of long polypeptide chains.
The key aspect of the native chemical ligation approach is reaction under conditions that promote exchange of the thiol moiety of the initial thioester-linked intermediate products, to give regioselective ligation at the N-terminal Cys even in the presence of other Cys residues in both segments (Dawson et al. Science 1994, 266, 776-779). By contrast, in the 'thiol capture' strategy and related methods (Liu et al. Tetrahedron Lett. 1996, 37, 933-936) regiospecific protection of Cys side chain functionalities prior to the ligation reaction is a necessity (Kemp et al. Peptides:
Proceedings of the 11th American Peptide Symposium Rivier, J.E.; Marshall, G.R., Eds, ESCOM: Lieden, 1990;
pp 920-922), thus frustrating their original intent.
Similarly, the use, in the current invention, of a carbonyl-activated a-thiocarboxyl function (i.e. an a-COSR) is reminiscent of chemistry previously used in peptide segment condensation (Blake et al. Proc. Nati.
Acad. Sci. USA 1981, 78, 4055-4058; Yamashiro et al.
Int. J. Pept. Protein Res. 1988, 31, 322-334; Hojo et al. Peptide Chemistry Okada, Y., Ed, Protein Research Foundation: Osaka, 1994; pp 9-12) However, these syntheses were based on conventional noN-chemoselective attack by the a-amine nucleophile of the second segment on a Ag+-activated peptide- 'COSR, and thus necessitated regiospecific (re)protection of all other a- and E-amine functional groups in both segments.
By contrast, thioester-mediated amide-forming ligation chemistry is compatible with the use of completely unprotected peptide segments with the full range of side chain functionalities found in nature, including thiols (Baca et al. J. Am. Chem. Soc. 1995, 117, 1881-1887; Dawson et al. Science 1994, 266, 776-779). For this reason, native chemical ligation is simple, practical, and is a general approach to the total chemical synthesis of proteins provided they contain appropriate ligation sites.
This invention increases the utility of the native chemical ligation method reported by Dawson, et al (Dawson et al. Science 1994, 266, 776-779) by extending the number of dipeptide sequences that can be used as ligation sites. In addition to the X-Cys ligation site of that methodology, it is disclosed herein how make use of X-Gly and Gly-X ligation sites (i.e. the C-terminal residue being glycine if the N-terminal residue is non-glycine or conversely, the N-terminal residue being glycine if the C-terminal residue is non-glycine). In the preferred mode, X is any of the non-B-branched amino acids. However, our previous studies have shown that X
can be any amino acid, including B-branched such as Val;(Dawson et al. Science 1994, 266, 776-779).
The invention potentially extends the number of suitable sites for native chemical ligation by a factor of three, to more than 50 of the 400 dipeptide sequences found in proteins. Because there is considerable latitude in choosing a ligation site in a target sequence which contains a glycine residue, this extended applicability will render most polypeptides accessible by native chemical ligation.
Native chemical ligation in its original form (Dawson et al. Science 1994, 266, 776-779) or in the form described here provides direct synthetic access to polypeptide chains the size of typical protein domains.
Other ligation chemistries (Schnolzer et al. Science 1992, 256, 221-225; Rose et al. Am. Chem. Soc. 1994, 116, 30-34; Liu et al. Proc. Natl. Acad. Sci. USA 1994, 91, 6584-6588) can be used to join synthetic domains in a modular fashion to produce large (i.e. >20 kilodalton), fully functional synthetic proteins (Canne et al. J. Am. Chem. Soc. 1995, 117, 2998-3007; Baca et al. J. Am. Chem. Soc. 1995, 117, 1881-1887). In its most general form, incorporating all suitable chemistries (Dawson et al. Science 1994, 266, 776-779) the chemical ligation approach represents the next stage in the evolution of methods for the chemical synthesis of polypeptides and, for the first time, provides for repoducible, practical total chemical synthesis of proteins.
Example Ligations 1-4 Results of example ligations are summarized in Figure 4. All ligations were run at concentrations ranging from 4 mgs/mL to 8 mgs/mL of each peptide in either 8M Urea, 0.1 M NaZHPOq, pH 7.0 or 6M
guanidine=HCl, 0.1 M Na2HPO41 pH 7.5. Immediately after solvation of the peptide segments, 2-5% benzyl mercaptan (example ligation #1) or thiophenol (example ligations #2-5), by volume of ligation buffer, was added to keep thiol functions in the reduced form. This had the added consequence of exchanging a significant amount of the original peptide= thioester (1) to a peptide "thiobenzyl ester or peptide "thiophenyl ester, both of which are still capable of reacting in the desired fashion with peptide 2. The ligation reactions were followed by analytical reverse-phase HPLC and the products identified by ESMS. In the following examples, the amino acid residues involved in the ligation are underlined.
Example The peptide= thio(3-carboxy-4-nitro)phenyl ester 1 had the sequence LYRA_Q- 'COSC6H3 ( 3-CO2H-4-NOZ ) (SEQ ID NO
1) (observed mass 760 Da, calcd 760 Da). The N '(ethanethiol) peptide 2a, protected as the 5-thio-2-(nitrobenzoic acid) disulfide, had the sequence [(3-CO2H-4-NO2 )-C6H3-S-SCH2CH2 ]--QAGPAGD- 'CONH2 (SEQ ID NO 2) (observed mass 800 Da, calcd 800 Da) which was reduced to [HSCH2CH2]-2AGPAGD= CONH2 (SEQ ID NO 2) (observed mass 603 Da, calcd 603 Da) in the ligation mixture. After one hour, the product of the ligation, 4a, [LYRA2G(N -CH2CH2SH)AGPAGD= CONH2 (SEQ ID NO 3) (observed mass 1163 1 Da, calcd 1163 Da)] had already formed to a significant degree. After purification of the ligation product by reverse phase HPLC, it was treated with 5,5'-dithio-bis(2-nitrobenzoic acid) for one hour in 6 M urea, 0.1 M
phosphate, pH 6.0 to yield the expected -S-nitrobenzoic acid disulfide product, LYRA22[N '-CH2CH2S-SC6H3(3-CO2H-4-N02) ]AGPAGD- 'CONHZ (SEQ ID NO 3) (observed mass 1360 1 Da, calcd 1360 Da). This confirmed the rearrangement of 3a to form 4a, since 3a would have been unreactive towards 5,5'-dithio-bis(2-nitrobenzoic acid). The results are summarized in Figure 4.
Example 2 Figures 5A-5C show the course of example ligation #2. The peptide-athioester segment 1 (peak a) had the SUBSTITUTE SHEET (RULE 26) sequence LYRAS-"COSC6H3 ( 3-CO2H, 4-NO2 )( SEQ ID NO 1) (observed mass 760 Da, calcd 760 Da). The N"(oxyethanethiol) peptide 2b (peak b) consisted of the sequence [HSCH2CH2O]-fzRNTATIMMQRGNFR-"CONH2 (SEQ ID NO 4) (observed mass 1827 1 Da, calcd 1828 Da). After one hour reaction at room temperature in the presence of added thiophenol, the ligation product, LYRASSz(N"-OCH2CH2SH) RNTATIMMQRGNFR= CONH2 (SEQ ID NO 5) (4b, observed mass 2388 1 Da, calcd 2389 Da) had formed to a significant degree, coeluting with unreacted N"(oxyethanethiol) peptide 2b (peak e). After further reaction overnight at room temperature, the ligation product was purified by HPLC and zinc dust was added directly to the collected peptide in HPLC eluant and stirred overnight at room temperature. Under these conditions, the zinc effectively reduced the N-O bond.
Reductions of this type are possible through a variety of reagents (Keck et al. Tetrahedron Lett. 1995, 36, 7419-7922). The resulting peptide (peak f) gave a mass consistent with reduction of the N-O bond to produce LYRA22RNTATIMMQRGNFR-"CONH2 (SEQ ID NO 5) (5b, observed mass 2313 1 Da, calcd 2313 Da). This confirmed the rearrangement of 3b to 4b as shown in Figure 1, since cleavage of the N-O bond in unrearranged 3b would have resulted in the formation of two distinct peptides of significantly lower masses.
Example 3 -Figures 6A-6C show the course of example ligation #3. The peptide- thioester segment 1 (peak d) consisted of a peptide with a C-terminal phenylalanine thioester (LYRAF--"COSCH2C6H5 (SEQ ID NO 6) (observed mass 775 Da, calcd 775 Da)), thus providing a more sterically hindered model than the previous cases (example ligations #1 and #2) which involved C-terminal glycine thioesters. The N (oxyethanethiol) peptide 2b (peak a) consisted of the sequence [HSCH2CH2O]--QRNTATIMMQRGNFR-SUBSTITUTE SHEET (RULE 26) 'CONH2 (SEQ ID NO 7) (observed mass 1827 1 Da, calcd 1828 Da). The presence of the more sterically hindered thioester slowed the reaction relative to the unhindered models. However, heating at 37 C was found to accelerate the rate of initial ligation. Figure 6A
illustrates the ligation reaction after 11.5 hours at 37 C. The rate of rearrangement of 3b to 4b was slowed enough to observe the unrearranged product 3b, LYRAF-[ COSCH2CH2O ] -QRNTATIMMQRGNFR- 'CONHz (SEQ ID NO 8) (peak b, observed mass 2478 1 Da, calcd 2478 Da), eluting slightly before the rearranged product 4b, LYRAM(N -OCHZCHZSH) RNTATIMMQRGNFR- 'CONH2 (SEQ ID NO 9) (peak c, observed mass 2478 1 Da, calcd 2478 Da). Having identical masses, the unrearranged and rearranged products, 3b and 4b, were identified by their zinc reduction products. Intermediate 3b, peak b, gave two peptides upon zinc reduction with masses of 669 Da and 1753 Da corresponding to the peptide sequences LYRAE-COOH (thioester hydrolysis) and fjRNTATIMMQRGNFR-0'CONH21 respectively. It was subsequently determined that lowering the pH to 4.5 after initial ligation by diluting the crude reaction mixture (to five times the volume) with 6M guanidine=HC1, 0.1 M Na acetate, pH 4.0 accelerated the rate of rearrangement. Figure 6B shows that rearrangement of the initial ligation product 3b to 4b (peak c) was complete after 10 hours at pH 4.5 at 37 C. HPLC purification of this peak and subsequent zinc reduction gave a peptide (peak f) of the expected mass, LYRAMRNTATIMMQRGNFR-"CONH2 (SEQ ID NO 9) (5b, observed mass 2403 1 Da, calcd 2404 Da).
Example 4 LYRAQ-"COSCH2C6H5 1(SEQ ID NO 1) (observed mass 685 Da, calcd 685 Da) was ligated to [HSCHZCH2O]-BARHTVHQRHLHG= COOH 2b (SEQ ID NO 10) (observed mass 1595 1 Da, calcd 1596 Da) at pH 7.5. This example provided steric hindrance, in the form of an Ala residue, on the opposite side of the ligation site from example ligation #3. The rate of reaction was similiar to that of example 3, the rate being significantly slower than the unhindered examples (example ligations #1 and #2), but enhanced with heating at 37 C. Both unrearranged (3b, LYRAS-"[COSCH2CH2O]-BARHTVHQRHLHG= COOH) (SEQ ID NO 11) and rearranged (4b, LYRA-GA(N '-OCH2CH2SH)ARHTVHQRHLHG= COOH) (SEQ ID NO 12) ligation products were formed, observed mass (both unrearranged and rearranged) 2156 1 Da, calcd 2157 Da. However, unlike example ligation #3, the rate of rearrangement was n2t enhanced by lowering the pH to 4.5 after initial ligation, though rearrangment was nearly complete after 2 days at 37 C regardless of pH as shown by successful reduction to the amide. It should also be noted that the presence of a significant number of histidines in the final ligation product 5b (LYRACjAARHTVHQRHLHG-"COOH
(SEQ ID NO 12), observed mass 2080 1 Da, calcd 2080 Da) resulted in binding of the peptide to the zinc. EDTA
had to be added to the HPLC buffer/Zn mixture to free the peptide from the zinc after reduction of the N-O
bond. The results are summarized in Figure 4.
Examr)le 5 Example 5 provides an example with steric bulk on both sides of the ligation site. LYRAf= COSCH2C6H5 1(SEQ
ID NO 6) (observed mass 775 Da, calcd 775 Da) was ligated to [HSCHZCH2O]-BARHTVHQRHLHG= COOH 2b (SEQ ID NO
13) (observed mass 1595 1 Da, calcd 1596 Da) at pH 7.5.
Though the initial (i.e. unrearranged) ligation product 3b was observed, LYRAE [COSCH2CHZ0]-BARHTVHQRHLHG= COOH
(SEQ ID NO 14) (observed mass 2246 1 Da, calcd 2247 Da), there was no evidence of rearrangement over time, even at lower pH. The presence of side chains on both sides of the ligation site apparently provided too much steric hindrance for the rearrangement to occur via a 6-membered ring intermediate under the conditions used.
-i8-The results are summarized in Figure 4.
The above examples emphasize the extraordinary facility of our original native ligation chemistry (Dawson et al. Science 1994, 266, 776-779) which recently was independently repeated in essentially identical form in model ligation studies (Tam et al.
Proc. Natl. Acad. Sci. USA 1995, 92, 12485-12489). We have used this original native peptide bond-forming ligation reaction in the chemical synthesis of a number of proteins with full biological activity, including the chemokine IL-8 (Dawson et al. Science 1994, 266, 776-779), the enzymes HIV-1 protease and barnase, the serine proteinase inhibitors turkey ovomucoid third domain and eglin C, and a b/HLH transcription factor. This ligation reaction was based on principles enunciated by Max Brenner (Brenner M. Peptides. Proceedings of the Eighth European Peptide Symposium Beyerman, H.C., Ed., North Holland: Amsterdam, 1976; pp 1-7) and made use of chemistry first described by Wieland (Wieland et al.
Liebigs Ann. Chem. 1953, 583, 129-149).
EXPERIMENTAL PROTOCALS
General Machine-assisted solid-phase peptide syntheses were carried out on a custom-modified Applied Biosystems 430A
peptide synthesizer (Schn6lzer et al. Int. J. Pept.
Protein Res. 1992, 40, 180-193). Reverse-phase HPLC was performed on a Rainin HPLC system with 214-nm UV
detection, using Vydac*C-18 analytical (5 gm, 0.46 X 15 cm) and semipreparative (10 /um, 1.0 X 25cm) columns.
Chromatographic separations were achieved using linear gradients of buffer B in A (A = 0.1% TFA in water, B=
90% CH3CN/10%water containing 0.09% TFA) over 30-60 min at 1 mL/min (analytical) or 3 mL/min (semipreparative).
Mass spectra of all peptide segments were obtained with *Trade-mark *
a Sciex API-III electrospray quadrupole mass spectrometer; observed masses were derived from the experimental m/z values for all observed protonation states of a molecular species, using the program MacSpec (Sciex). Calculated masses were based on average isotope composition and were derived using the program MacProMass (Terry Lee and Sunil Vemuri, Beckman Research Institute, Duarte, CA). All other mass spectrometry was performed at The Scripps Research Institute Mass Spectrometry Facility. 1H NMR spectra were recorded on a Bruker*250 MHz spectrophotometer and chemical shifts are reported in parts per million downfield from Me4Si.
Microanalyses were performed at The Scripps Research Institute X-ray Crystallographic Facility and agreed with calculated values 0.4%. BoC-L-amino acids and HBTU were purchased from Novabiochem (La Jolla, CA). 4-Hydromethylphenylacetamidomethyl (PAM) resins and diisopropylethylamine (DIEA) were obtained from Applied Biosystems (Foster City, CA), and methylbenzhydrylamine (MBHA) resin was obtained from Peninsula Laboratories, Inc (San Carlos, CA). Synthesis grade dimethylformamide (DMF) was obtained from Baker, and AR grade CH2C12 and HPLC-grade CH3CN obtained from Fisher. Trifluoroacetic acid (TFA) was obtained from Halocarbon (New Jersey).
HF was purchased from Matheson Gas. 4-Methylbenzyl mercaptan was obtained from Lancaster. All other reagents were AR grade or better and were obtained from Aldrich Chemical or from Fisher.
Peptide Segment Synthesis Chain Assembly Peptides were synthesized in stepwise fashion by established machine-assisted or manual solid-phase methods using in situ neutralization/HBTU activation protocols for Boc chemistry (Schnolzer et al. Int. J.
Pept. Protein Res. 1992, 40, 180-193). Side chain protection was as follows: BoC-Arg(p-toluenesulfonyl)-OH, BoC-Asn(xanthyl)-OH, BoC-Asp(O-cyclohexyl)-OH, BoC-*Trade-mark His(dinitrophenyl)-OH, BoC-Thr(benzyl)-OH, and BoC-Tyr(2-bromobenzyloxycarbonyl)-OH. BoC-G1N-OH and BoC-Met-OH were used without side chain protection.
Coupling reactions were monitored by quantitative ninhydrin assay (Sarin et al Anal. Biochem. 1981, 117, 147-157) and were typically >99%. After chain assembly was complete, peptides were deprotected and simultaneously cleaved from the resin by treatment with HF containing 5% p-cresol for 1 h at 0OC to give the peptide= COSH, - CONH21 or = C02H. After removal of the HF under reduced pressure, the crude peptide was precipitated in anhydrous Et20 (diethyl ether), dissolved in HPLC buffer (40-50% B) and lyophilized.
Synthesis of Pentide= thioesters (1) as shown in Figure 1 Thioacid peptides were synthesized on the appropriate BoC-aminoacyl-S-Resins, made by coupling [4-[a-(N-t-BoC-aminoacyl-S)benzyl]phenoxy]acetic acid, DCHA
salt (Canne et al. Tetrahedron Lett. 1995, 36, 1217-1220), (2.0 equiv) and aminomethyl-resin (1 equiv, washed with 10% DIEA in DMF; Aldrich) with HBTU (1.6 equiv; Aldrich) added as an activating agent and DIEA (1 equiv; Aldrich), in DMF (dimethylformamide). Peptide-COSC6H3(3-CO2H-4-NO2) thioesters were generated by dissolving the crude peptide- COSH (15-20 mgs) in 6 M
guanidine=HC1, 0.1 M Na Acetate, pH 5.0-6.5, to which was added 1.5 equivalents of 5,51-dithio-bis(2-nitrobenzoic acid) (Dawson et al. Science 1994, 266, 776-779). The mixture was vortexed briefly and purified after 10 min. Identity of the peptide-'COSC6H3(3-CO2H-4-NO2) ester was unambigously confirmed by precise electrospray mass measurements, in contrast with Liu et al. Tetrahedron Lett. 1996, 37, 933-936.
Peptide- 'COSCH2C6H5 thioesters were generated by dissolving the crude peptide "COSH (15-20 mgs) in 6M
guanidine*HC1, 0.1 M Na acetate, pH 4.0, to which was added 10 equivalents of benzyl bromide (Dawson et al.
Science 1994, 266, 776-779). The mixture was vortexed briefly and purified after 1 h. LYRAf.= COSC6H3 (3-CO2H-4-NO2) (observed mass 760 Da, calcd 760 Da) was purified by semipreparative HPLC (20-60%B over 40 min) to give 20-30% yield. LYRPfi- COSCH2C6H5 (observed mass 685 Da, calcd 685 Da) was purified by semipreparative HPLC (15-45%B
over 60 min) to give 25-30% yield. LYRAE-"COSCHZC6H5 (observed mass 775 Da, calcd 775 Da) was purified by semipreparative HPLC (30-60%B over 60 min) to give 25-30% yield. Most of the loses in yield arose simply from HPLC recoveries.
Synthesis of N '(ethanethiol) and N"(oxyethanethiol) peptides (2) as illustrated in Figure 2 These peptides were synthesized on either MBHA
(Sigma)or the appropriate BoC-aminoacyl-OCH2-PAM-resins (Sigma). After chain assembly was complete and the N Boc group removed with neat TFA (two 1 min treatments) and neutralized with 10% DIEA in DMF (two 1 min treatments), the peptide was bromoacetylated by the method of Robey (Robey et al. Anal. Biochem. 1989, 177, 373-377).
Bromoacetic acid (2.0 mmol) was dissolved in CH2C12 (2 mL) to which was added DIC (1 mmol; 2-dimethylaminoisopropyl chloride hydrochloride; Aldrich or Sigma). After activation for 10-15 min to form the symmetric anhydride, the mixture was diluted with DMF (2 mL), added to the peptide-resin and coupled for 30 min.
The resin was then washed with DMSO and 8a (2 M in DMSO) or 8b (1 M in DMSO) was added and allowed to react with the bromoacetylated peptide-resin for 8-23 h. The peptides were purified without further modifcation after cleavage from the resin. [ (3-CO2H-4-N02)-C6H3-S-SCH2CH2]-BGPAGD= CONH2 (2a) (observed mass 800 Da, calcd 800 Da) was purified by semipreparative HPLC (0-67%B over 60 min) to give "24$ yield. [HSCH2CH2O]-faRNTATIMMQRGNFR-"CONHZ (2b) (observed mass 1827 1 Da, calcd 1828 Da) was purified by semipreparative HPLC (15-40%B over 60 min) to give "25% yield. [HSCH2CHZO]-BARHTVHQRHLHG-aCOOH
(2b) was synthesized by the above method using the racemate of 2-bromoproprionic acid instead of bromoacetic acid. The resulting crude lyophilized product was a mixture of the desired peptide and the peptide that results from elimination of HBr from the bromopropionylated peptide (CH2=CHC0-ARHTVHQRHLHG= COOH, observed mass 1502 1 Da, calcd 1502 Da). The mixture was purified by semipreparative HPLC (10-40%B over 60 min) to give [HSCH2CH201-AARHTVHQRHLHG-aCOOH (observed mass 1595 1 Da, calcd 1596 Da) in -10% yield.
Synthesis of S-[(3-Carboxy-4-nitro)tiõhenyltt,;nl-2-aminoethanethiol (8a) as shown in Figure 2 2-Aminoethanethiol (1.0 g, 13.0 mmol) and 5,5'-dithio-bis(2-nitrobenzoic acid) (1.75 g, 4.4 mmol) were combined in acetonitrile (100 mL) and water (25 mL) and stirred at room temperature for 14 hr. The reaction mixture was diluted with water (450 mL) and purified by preparative reverse phase HPLC on a Waters Delta Prep 4000 with a Vydac 5.0 x 2.5 cm preparative C-18 column to give Sa (1.0 g, 40%) 1H NMR (D20) : b 7.95 (d, 1H, J=8.7 Hz), 7.61 (dd, 1H, J=8.7, 2.2 Hz), 7.58 (d, 1H, J=2.2 Hz), 3.18 (t, 2H, J=6.5 Hz), 2.92 (t, 2H, J=6.7 Hz).
Synthesis of N-(2-Bromoethoxy)phthalimide (11) as illustrated in Figure 3.
N-(2-Bromoethoxy)phthalimide (11) was synthesized by a modification of the procedure of Bauer and Sureshl (Bauer et al. J. Org. Chem. 1963, 28, 1604-1608). N-Hydroxyphthalimide (16.0 g, 98 mmol; Aldrich), triethylamine (30 mL, 215 mmol), and 1,2-dibromoethane (35 mL, 406 mmol; Aldrich) were combined in DMF (115 mL) and stirred at room temperature overnight. Solids were filtered and washed with DMF. The filtrate was diluted with water (800 mL) and the resulting precipitate filtered, dissolved in EtOAc (200 mL) and washed with 1 N HC1 (2 x 50 mL), water (1 x 50 mL), saturated NaCl (1 x 50 mL) and dried over MgS09. Volatiles were removed in vacuo and the resulting solid was recrystallized from 95% EtOH to give 11 as a white solid (16.6 g, 63%). 1H
NMR (CDC13): b 7.82 (m, 4H), 4.49 (t, 2H, J=6.9 Hz), 3.65 (t, 2H, J=6.9 Hz); FAB MS (sodium ion): calc for [C10HeBrNO3, H+] 291.9585, found 291.9579.
Synthesis of N-[2-[S-(4-Methylbenzyl)]mercapto]ethoxvl nhthalimide (12) as illustrated in Figure 3 Bromide 11 (16.6, 62 mmol), 4-methylbenzyl mercaptan (8.5 mL, 63 mmol), and DBU (9.5 mL, 64 mmol; 1,8-diazabicyclo[5.4.0]undeC-7-ene; Aldrich) were combined in benzene (150 mL) and stirred at room temperature for 8 hr. Solids were filtered, washed with benzene and the filtrate washed with 1 N HC1 (2 x 35 mL), water (1 x 35 mL), saturated NaCl (1 x 35 mL) and dried over MgSO9.
Volatiles were removed in vacuo and the resulting solid recrystallized from EtOAc/hexane to yield 12 as a white solid (14.8 g, 74%) 1H NMR (CDC13): S 7.80 (m, 4H), 7.18 (d, 2H, J=8.0 Hz), 7.04 (d, 2H, J=8.0 Hz), 4.22 (t, 2H, J=7.4 Hz), 3.75 (s, 2H), 2.79 (t, 2H, J=7.4 Hz), 2.27 (s, 3H) ; FAB MS: calc for [C18H17N03S, H+] 328.1007, found 328.1016. Anal. Calcd for C18H1-7NO3S C, 66.03; H, 5.23; N, 4.28; S, 9.79. Found C, 66.04; H, 4.95; N, 4.30; S, 9.58.
Synthesis of S-(4-Methylbenzyl)-2-aminooxyethanethiQj.
(8b) as illustrated in Figure 3 S-(4-methylbenzyl)-2-aminooxyethanethiol was synthesized by the method of Osby (Osby et al.
Tetrahedron Lett. 1984, 25, 2093-2096). The N-substituted phthalimide 12 (7.4 g, 23 mmol) was suspended in isopropanol (203 mL) and water (35 mL) to which was added NaBH4 (3.5 g, 92 mmol). The mixture was stirred at room temperature overnight. Acetic acid (25 mL) was slowly added till bubbling ceased, the flask stoppered and heated to 50 C for 2-3 hr. Volatiles were removed in vacuo, the resulting solution diluted with 1 N NaOH and extracted with EtOAc (4 x 50 mL). The combined EtOAc extractions were washed with saturated NaCl (1 x 50 mL) and dried over MgSO9. Volatiles were removed in vacuo and the resulting oil purified by flash chromatography (1:1 hexane:EtOAc) to yield 8b as a clear, colorless oil (3.2 g, 72%) 'H NMR (CDC13): 6 7.21 (d, 2H, J=8.0 Hz), 7.12 (d, 2H, J=8.0 Hz), 5.40 (br s, 2H, D20 ex.), 3.77 (t, 2H, J=6.5 Hz), 3.71 (s, 2H), 2.64 (t, 2H, J=6.5 Hz), 2.33 (s, 3H); FAB MS: calc for [C1oH1sNOS, H'] 198.0953, found 198.0958. Anal.
Calcd for C10H15NOS C, 60.88; H, 7.66; N, 7.10; S, 16.25.
Found C, 60.79; H, 7.88; N, 7.03; S, 16.11.
By contrast, thioester-mediated amide-forming ligation chemistry is compatible with the use of completely unprotected peptide segments with the full range of side chain functionalities found in nature, including thiols (Baca et al. J. Am. Chem. Soc. 1995, 117, 1881-1887; Dawson et al. Science 1994, 266, 776-779). For this reason, native chemical ligation is simple, practical, and is a general approach to the total chemical synthesis of proteins provided they contain appropriate ligation sites.
This invention increases the utility of the native chemical ligation method reported by Dawson, et al (Dawson et al. Science 1994, 266, 776-779) by extending the number of dipeptide sequences that can be used as ligation sites. In addition to the X-Cys ligation site of that methodology, it is disclosed herein how make use of X-Gly and Gly-X ligation sites (i.e. the C-terminal residue being glycine if the N-terminal residue is non-glycine or conversely, the N-terminal residue being glycine if the C-terminal residue is non-glycine). In the preferred mode, X is any of the non-B-branched amino acids. However, our previous studies have shown that X
can be any amino acid, including B-branched such as Val;(Dawson et al. Science 1994, 266, 776-779).
The invention potentially extends the number of suitable sites for native chemical ligation by a factor of three, to more than 50 of the 400 dipeptide sequences found in proteins. Because there is considerable latitude in choosing a ligation site in a target sequence which contains a glycine residue, this extended applicability will render most polypeptides accessible by native chemical ligation.
Native chemical ligation in its original form (Dawson et al. Science 1994, 266, 776-779) or in the form described here provides direct synthetic access to polypeptide chains the size of typical protein domains.
Other ligation chemistries (Schnolzer et al. Science 1992, 256, 221-225; Rose et al. Am. Chem. Soc. 1994, 116, 30-34; Liu et al. Proc. Natl. Acad. Sci. USA 1994, 91, 6584-6588) can be used to join synthetic domains in a modular fashion to produce large (i.e. >20 kilodalton), fully functional synthetic proteins (Canne et al. J. Am. Chem. Soc. 1995, 117, 2998-3007; Baca et al. J. Am. Chem. Soc. 1995, 117, 1881-1887). In its most general form, incorporating all suitable chemistries (Dawson et al. Science 1994, 266, 776-779) the chemical ligation approach represents the next stage in the evolution of methods for the chemical synthesis of polypeptides and, for the first time, provides for repoducible, practical total chemical synthesis of proteins.
Example Ligations 1-4 Results of example ligations are summarized in Figure 4. All ligations were run at concentrations ranging from 4 mgs/mL to 8 mgs/mL of each peptide in either 8M Urea, 0.1 M NaZHPOq, pH 7.0 or 6M
guanidine=HCl, 0.1 M Na2HPO41 pH 7.5. Immediately after solvation of the peptide segments, 2-5% benzyl mercaptan (example ligation #1) or thiophenol (example ligations #2-5), by volume of ligation buffer, was added to keep thiol functions in the reduced form. This had the added consequence of exchanging a significant amount of the original peptide= thioester (1) to a peptide "thiobenzyl ester or peptide "thiophenyl ester, both of which are still capable of reacting in the desired fashion with peptide 2. The ligation reactions were followed by analytical reverse-phase HPLC and the products identified by ESMS. In the following examples, the amino acid residues involved in the ligation are underlined.
Example The peptide= thio(3-carboxy-4-nitro)phenyl ester 1 had the sequence LYRA_Q- 'COSC6H3 ( 3-CO2H-4-NOZ ) (SEQ ID NO
1) (observed mass 760 Da, calcd 760 Da). The N '(ethanethiol) peptide 2a, protected as the 5-thio-2-(nitrobenzoic acid) disulfide, had the sequence [(3-CO2H-4-NO2 )-C6H3-S-SCH2CH2 ]--QAGPAGD- 'CONH2 (SEQ ID NO 2) (observed mass 800 Da, calcd 800 Da) which was reduced to [HSCH2CH2]-2AGPAGD= CONH2 (SEQ ID NO 2) (observed mass 603 Da, calcd 603 Da) in the ligation mixture. After one hour, the product of the ligation, 4a, [LYRA2G(N -CH2CH2SH)AGPAGD= CONH2 (SEQ ID NO 3) (observed mass 1163 1 Da, calcd 1163 Da)] had already formed to a significant degree. After purification of the ligation product by reverse phase HPLC, it was treated with 5,5'-dithio-bis(2-nitrobenzoic acid) for one hour in 6 M urea, 0.1 M
phosphate, pH 6.0 to yield the expected -S-nitrobenzoic acid disulfide product, LYRA22[N '-CH2CH2S-SC6H3(3-CO2H-4-N02) ]AGPAGD- 'CONHZ (SEQ ID NO 3) (observed mass 1360 1 Da, calcd 1360 Da). This confirmed the rearrangement of 3a to form 4a, since 3a would have been unreactive towards 5,5'-dithio-bis(2-nitrobenzoic acid). The results are summarized in Figure 4.
Example 2 Figures 5A-5C show the course of example ligation #2. The peptide-athioester segment 1 (peak a) had the SUBSTITUTE SHEET (RULE 26) sequence LYRAS-"COSC6H3 ( 3-CO2H, 4-NO2 )( SEQ ID NO 1) (observed mass 760 Da, calcd 760 Da). The N"(oxyethanethiol) peptide 2b (peak b) consisted of the sequence [HSCH2CH2O]-fzRNTATIMMQRGNFR-"CONH2 (SEQ ID NO 4) (observed mass 1827 1 Da, calcd 1828 Da). After one hour reaction at room temperature in the presence of added thiophenol, the ligation product, LYRASSz(N"-OCH2CH2SH) RNTATIMMQRGNFR= CONH2 (SEQ ID NO 5) (4b, observed mass 2388 1 Da, calcd 2389 Da) had formed to a significant degree, coeluting with unreacted N"(oxyethanethiol) peptide 2b (peak e). After further reaction overnight at room temperature, the ligation product was purified by HPLC and zinc dust was added directly to the collected peptide in HPLC eluant and stirred overnight at room temperature. Under these conditions, the zinc effectively reduced the N-O bond.
Reductions of this type are possible through a variety of reagents (Keck et al. Tetrahedron Lett. 1995, 36, 7419-7922). The resulting peptide (peak f) gave a mass consistent with reduction of the N-O bond to produce LYRA22RNTATIMMQRGNFR-"CONH2 (SEQ ID NO 5) (5b, observed mass 2313 1 Da, calcd 2313 Da). This confirmed the rearrangement of 3b to 4b as shown in Figure 1, since cleavage of the N-O bond in unrearranged 3b would have resulted in the formation of two distinct peptides of significantly lower masses.
Example 3 -Figures 6A-6C show the course of example ligation #3. The peptide- thioester segment 1 (peak d) consisted of a peptide with a C-terminal phenylalanine thioester (LYRAF--"COSCH2C6H5 (SEQ ID NO 6) (observed mass 775 Da, calcd 775 Da)), thus providing a more sterically hindered model than the previous cases (example ligations #1 and #2) which involved C-terminal glycine thioesters. The N (oxyethanethiol) peptide 2b (peak a) consisted of the sequence [HSCH2CH2O]--QRNTATIMMQRGNFR-SUBSTITUTE SHEET (RULE 26) 'CONH2 (SEQ ID NO 7) (observed mass 1827 1 Da, calcd 1828 Da). The presence of the more sterically hindered thioester slowed the reaction relative to the unhindered models. However, heating at 37 C was found to accelerate the rate of initial ligation. Figure 6A
illustrates the ligation reaction after 11.5 hours at 37 C. The rate of rearrangement of 3b to 4b was slowed enough to observe the unrearranged product 3b, LYRAF-[ COSCH2CH2O ] -QRNTATIMMQRGNFR- 'CONHz (SEQ ID NO 8) (peak b, observed mass 2478 1 Da, calcd 2478 Da), eluting slightly before the rearranged product 4b, LYRAM(N -OCHZCHZSH) RNTATIMMQRGNFR- 'CONH2 (SEQ ID NO 9) (peak c, observed mass 2478 1 Da, calcd 2478 Da). Having identical masses, the unrearranged and rearranged products, 3b and 4b, were identified by their zinc reduction products. Intermediate 3b, peak b, gave two peptides upon zinc reduction with masses of 669 Da and 1753 Da corresponding to the peptide sequences LYRAE-COOH (thioester hydrolysis) and fjRNTATIMMQRGNFR-0'CONH21 respectively. It was subsequently determined that lowering the pH to 4.5 after initial ligation by diluting the crude reaction mixture (to five times the volume) with 6M guanidine=HC1, 0.1 M Na acetate, pH 4.0 accelerated the rate of rearrangement. Figure 6B shows that rearrangement of the initial ligation product 3b to 4b (peak c) was complete after 10 hours at pH 4.5 at 37 C. HPLC purification of this peak and subsequent zinc reduction gave a peptide (peak f) of the expected mass, LYRAMRNTATIMMQRGNFR-"CONH2 (SEQ ID NO 9) (5b, observed mass 2403 1 Da, calcd 2404 Da).
Example 4 LYRAQ-"COSCH2C6H5 1(SEQ ID NO 1) (observed mass 685 Da, calcd 685 Da) was ligated to [HSCHZCH2O]-BARHTVHQRHLHG= COOH 2b (SEQ ID NO 10) (observed mass 1595 1 Da, calcd 1596 Da) at pH 7.5. This example provided steric hindrance, in the form of an Ala residue, on the opposite side of the ligation site from example ligation #3. The rate of reaction was similiar to that of example 3, the rate being significantly slower than the unhindered examples (example ligations #1 and #2), but enhanced with heating at 37 C. Both unrearranged (3b, LYRAS-"[COSCH2CH2O]-BARHTVHQRHLHG= COOH) (SEQ ID NO 11) and rearranged (4b, LYRA-GA(N '-OCH2CH2SH)ARHTVHQRHLHG= COOH) (SEQ ID NO 12) ligation products were formed, observed mass (both unrearranged and rearranged) 2156 1 Da, calcd 2157 Da. However, unlike example ligation #3, the rate of rearrangement was n2t enhanced by lowering the pH to 4.5 after initial ligation, though rearrangment was nearly complete after 2 days at 37 C regardless of pH as shown by successful reduction to the amide. It should also be noted that the presence of a significant number of histidines in the final ligation product 5b (LYRACjAARHTVHQRHLHG-"COOH
(SEQ ID NO 12), observed mass 2080 1 Da, calcd 2080 Da) resulted in binding of the peptide to the zinc. EDTA
had to be added to the HPLC buffer/Zn mixture to free the peptide from the zinc after reduction of the N-O
bond. The results are summarized in Figure 4.
Examr)le 5 Example 5 provides an example with steric bulk on both sides of the ligation site. LYRAf= COSCH2C6H5 1(SEQ
ID NO 6) (observed mass 775 Da, calcd 775 Da) was ligated to [HSCHZCH2O]-BARHTVHQRHLHG= COOH 2b (SEQ ID NO
13) (observed mass 1595 1 Da, calcd 1596 Da) at pH 7.5.
Though the initial (i.e. unrearranged) ligation product 3b was observed, LYRAE [COSCH2CHZ0]-BARHTVHQRHLHG= COOH
(SEQ ID NO 14) (observed mass 2246 1 Da, calcd 2247 Da), there was no evidence of rearrangement over time, even at lower pH. The presence of side chains on both sides of the ligation site apparently provided too much steric hindrance for the rearrangement to occur via a 6-membered ring intermediate under the conditions used.
-i8-The results are summarized in Figure 4.
The above examples emphasize the extraordinary facility of our original native ligation chemistry (Dawson et al. Science 1994, 266, 776-779) which recently was independently repeated in essentially identical form in model ligation studies (Tam et al.
Proc. Natl. Acad. Sci. USA 1995, 92, 12485-12489). We have used this original native peptide bond-forming ligation reaction in the chemical synthesis of a number of proteins with full biological activity, including the chemokine IL-8 (Dawson et al. Science 1994, 266, 776-779), the enzymes HIV-1 protease and barnase, the serine proteinase inhibitors turkey ovomucoid third domain and eglin C, and a b/HLH transcription factor. This ligation reaction was based on principles enunciated by Max Brenner (Brenner M. Peptides. Proceedings of the Eighth European Peptide Symposium Beyerman, H.C., Ed., North Holland: Amsterdam, 1976; pp 1-7) and made use of chemistry first described by Wieland (Wieland et al.
Liebigs Ann. Chem. 1953, 583, 129-149).
EXPERIMENTAL PROTOCALS
General Machine-assisted solid-phase peptide syntheses were carried out on a custom-modified Applied Biosystems 430A
peptide synthesizer (Schn6lzer et al. Int. J. Pept.
Protein Res. 1992, 40, 180-193). Reverse-phase HPLC was performed on a Rainin HPLC system with 214-nm UV
detection, using Vydac*C-18 analytical (5 gm, 0.46 X 15 cm) and semipreparative (10 /um, 1.0 X 25cm) columns.
Chromatographic separations were achieved using linear gradients of buffer B in A (A = 0.1% TFA in water, B=
90% CH3CN/10%water containing 0.09% TFA) over 30-60 min at 1 mL/min (analytical) or 3 mL/min (semipreparative).
Mass spectra of all peptide segments were obtained with *Trade-mark *
a Sciex API-III electrospray quadrupole mass spectrometer; observed masses were derived from the experimental m/z values for all observed protonation states of a molecular species, using the program MacSpec (Sciex). Calculated masses were based on average isotope composition and were derived using the program MacProMass (Terry Lee and Sunil Vemuri, Beckman Research Institute, Duarte, CA). All other mass spectrometry was performed at The Scripps Research Institute Mass Spectrometry Facility. 1H NMR spectra were recorded on a Bruker*250 MHz spectrophotometer and chemical shifts are reported in parts per million downfield from Me4Si.
Microanalyses were performed at The Scripps Research Institute X-ray Crystallographic Facility and agreed with calculated values 0.4%. BoC-L-amino acids and HBTU were purchased from Novabiochem (La Jolla, CA). 4-Hydromethylphenylacetamidomethyl (PAM) resins and diisopropylethylamine (DIEA) were obtained from Applied Biosystems (Foster City, CA), and methylbenzhydrylamine (MBHA) resin was obtained from Peninsula Laboratories, Inc (San Carlos, CA). Synthesis grade dimethylformamide (DMF) was obtained from Baker, and AR grade CH2C12 and HPLC-grade CH3CN obtained from Fisher. Trifluoroacetic acid (TFA) was obtained from Halocarbon (New Jersey).
HF was purchased from Matheson Gas. 4-Methylbenzyl mercaptan was obtained from Lancaster. All other reagents were AR grade or better and were obtained from Aldrich Chemical or from Fisher.
Peptide Segment Synthesis Chain Assembly Peptides were synthesized in stepwise fashion by established machine-assisted or manual solid-phase methods using in situ neutralization/HBTU activation protocols for Boc chemistry (Schnolzer et al. Int. J.
Pept. Protein Res. 1992, 40, 180-193). Side chain protection was as follows: BoC-Arg(p-toluenesulfonyl)-OH, BoC-Asn(xanthyl)-OH, BoC-Asp(O-cyclohexyl)-OH, BoC-*Trade-mark His(dinitrophenyl)-OH, BoC-Thr(benzyl)-OH, and BoC-Tyr(2-bromobenzyloxycarbonyl)-OH. BoC-G1N-OH and BoC-Met-OH were used without side chain protection.
Coupling reactions were monitored by quantitative ninhydrin assay (Sarin et al Anal. Biochem. 1981, 117, 147-157) and were typically >99%. After chain assembly was complete, peptides were deprotected and simultaneously cleaved from the resin by treatment with HF containing 5% p-cresol for 1 h at 0OC to give the peptide= COSH, - CONH21 or = C02H. After removal of the HF under reduced pressure, the crude peptide was precipitated in anhydrous Et20 (diethyl ether), dissolved in HPLC buffer (40-50% B) and lyophilized.
Synthesis of Pentide= thioesters (1) as shown in Figure 1 Thioacid peptides were synthesized on the appropriate BoC-aminoacyl-S-Resins, made by coupling [4-[a-(N-t-BoC-aminoacyl-S)benzyl]phenoxy]acetic acid, DCHA
salt (Canne et al. Tetrahedron Lett. 1995, 36, 1217-1220), (2.0 equiv) and aminomethyl-resin (1 equiv, washed with 10% DIEA in DMF; Aldrich) with HBTU (1.6 equiv; Aldrich) added as an activating agent and DIEA (1 equiv; Aldrich), in DMF (dimethylformamide). Peptide-COSC6H3(3-CO2H-4-NO2) thioesters were generated by dissolving the crude peptide- COSH (15-20 mgs) in 6 M
guanidine=HC1, 0.1 M Na Acetate, pH 5.0-6.5, to which was added 1.5 equivalents of 5,51-dithio-bis(2-nitrobenzoic acid) (Dawson et al. Science 1994, 266, 776-779). The mixture was vortexed briefly and purified after 10 min. Identity of the peptide-'COSC6H3(3-CO2H-4-NO2) ester was unambigously confirmed by precise electrospray mass measurements, in contrast with Liu et al. Tetrahedron Lett. 1996, 37, 933-936.
Peptide- 'COSCH2C6H5 thioesters were generated by dissolving the crude peptide "COSH (15-20 mgs) in 6M
guanidine*HC1, 0.1 M Na acetate, pH 4.0, to which was added 10 equivalents of benzyl bromide (Dawson et al.
Science 1994, 266, 776-779). The mixture was vortexed briefly and purified after 1 h. LYRAf.= COSC6H3 (3-CO2H-4-NO2) (observed mass 760 Da, calcd 760 Da) was purified by semipreparative HPLC (20-60%B over 40 min) to give 20-30% yield. LYRPfi- COSCH2C6H5 (observed mass 685 Da, calcd 685 Da) was purified by semipreparative HPLC (15-45%B
over 60 min) to give 25-30% yield. LYRAE-"COSCHZC6H5 (observed mass 775 Da, calcd 775 Da) was purified by semipreparative HPLC (30-60%B over 60 min) to give 25-30% yield. Most of the loses in yield arose simply from HPLC recoveries.
Synthesis of N '(ethanethiol) and N"(oxyethanethiol) peptides (2) as illustrated in Figure 2 These peptides were synthesized on either MBHA
(Sigma)or the appropriate BoC-aminoacyl-OCH2-PAM-resins (Sigma). After chain assembly was complete and the N Boc group removed with neat TFA (two 1 min treatments) and neutralized with 10% DIEA in DMF (two 1 min treatments), the peptide was bromoacetylated by the method of Robey (Robey et al. Anal. Biochem. 1989, 177, 373-377).
Bromoacetic acid (2.0 mmol) was dissolved in CH2C12 (2 mL) to which was added DIC (1 mmol; 2-dimethylaminoisopropyl chloride hydrochloride; Aldrich or Sigma). After activation for 10-15 min to form the symmetric anhydride, the mixture was diluted with DMF (2 mL), added to the peptide-resin and coupled for 30 min.
The resin was then washed with DMSO and 8a (2 M in DMSO) or 8b (1 M in DMSO) was added and allowed to react with the bromoacetylated peptide-resin for 8-23 h. The peptides were purified without further modifcation after cleavage from the resin. [ (3-CO2H-4-N02)-C6H3-S-SCH2CH2]-BGPAGD= CONH2 (2a) (observed mass 800 Da, calcd 800 Da) was purified by semipreparative HPLC (0-67%B over 60 min) to give "24$ yield. [HSCH2CH2O]-faRNTATIMMQRGNFR-"CONHZ (2b) (observed mass 1827 1 Da, calcd 1828 Da) was purified by semipreparative HPLC (15-40%B over 60 min) to give "25% yield. [HSCH2CHZO]-BARHTVHQRHLHG-aCOOH
(2b) was synthesized by the above method using the racemate of 2-bromoproprionic acid instead of bromoacetic acid. The resulting crude lyophilized product was a mixture of the desired peptide and the peptide that results from elimination of HBr from the bromopropionylated peptide (CH2=CHC0-ARHTVHQRHLHG= COOH, observed mass 1502 1 Da, calcd 1502 Da). The mixture was purified by semipreparative HPLC (10-40%B over 60 min) to give [HSCH2CH201-AARHTVHQRHLHG-aCOOH (observed mass 1595 1 Da, calcd 1596 Da) in -10% yield.
Synthesis of S-[(3-Carboxy-4-nitro)tiõhenyltt,;nl-2-aminoethanethiol (8a) as shown in Figure 2 2-Aminoethanethiol (1.0 g, 13.0 mmol) and 5,5'-dithio-bis(2-nitrobenzoic acid) (1.75 g, 4.4 mmol) were combined in acetonitrile (100 mL) and water (25 mL) and stirred at room temperature for 14 hr. The reaction mixture was diluted with water (450 mL) and purified by preparative reverse phase HPLC on a Waters Delta Prep 4000 with a Vydac 5.0 x 2.5 cm preparative C-18 column to give Sa (1.0 g, 40%) 1H NMR (D20) : b 7.95 (d, 1H, J=8.7 Hz), 7.61 (dd, 1H, J=8.7, 2.2 Hz), 7.58 (d, 1H, J=2.2 Hz), 3.18 (t, 2H, J=6.5 Hz), 2.92 (t, 2H, J=6.7 Hz).
Synthesis of N-(2-Bromoethoxy)phthalimide (11) as illustrated in Figure 3.
N-(2-Bromoethoxy)phthalimide (11) was synthesized by a modification of the procedure of Bauer and Sureshl (Bauer et al. J. Org. Chem. 1963, 28, 1604-1608). N-Hydroxyphthalimide (16.0 g, 98 mmol; Aldrich), triethylamine (30 mL, 215 mmol), and 1,2-dibromoethane (35 mL, 406 mmol; Aldrich) were combined in DMF (115 mL) and stirred at room temperature overnight. Solids were filtered and washed with DMF. The filtrate was diluted with water (800 mL) and the resulting precipitate filtered, dissolved in EtOAc (200 mL) and washed with 1 N HC1 (2 x 50 mL), water (1 x 50 mL), saturated NaCl (1 x 50 mL) and dried over MgS09. Volatiles were removed in vacuo and the resulting solid was recrystallized from 95% EtOH to give 11 as a white solid (16.6 g, 63%). 1H
NMR (CDC13): b 7.82 (m, 4H), 4.49 (t, 2H, J=6.9 Hz), 3.65 (t, 2H, J=6.9 Hz); FAB MS (sodium ion): calc for [C10HeBrNO3, H+] 291.9585, found 291.9579.
Synthesis of N-[2-[S-(4-Methylbenzyl)]mercapto]ethoxvl nhthalimide (12) as illustrated in Figure 3 Bromide 11 (16.6, 62 mmol), 4-methylbenzyl mercaptan (8.5 mL, 63 mmol), and DBU (9.5 mL, 64 mmol; 1,8-diazabicyclo[5.4.0]undeC-7-ene; Aldrich) were combined in benzene (150 mL) and stirred at room temperature for 8 hr. Solids were filtered, washed with benzene and the filtrate washed with 1 N HC1 (2 x 35 mL), water (1 x 35 mL), saturated NaCl (1 x 35 mL) and dried over MgSO9.
Volatiles were removed in vacuo and the resulting solid recrystallized from EtOAc/hexane to yield 12 as a white solid (14.8 g, 74%) 1H NMR (CDC13): S 7.80 (m, 4H), 7.18 (d, 2H, J=8.0 Hz), 7.04 (d, 2H, J=8.0 Hz), 4.22 (t, 2H, J=7.4 Hz), 3.75 (s, 2H), 2.79 (t, 2H, J=7.4 Hz), 2.27 (s, 3H) ; FAB MS: calc for [C18H17N03S, H+] 328.1007, found 328.1016. Anal. Calcd for C18H1-7NO3S C, 66.03; H, 5.23; N, 4.28; S, 9.79. Found C, 66.04; H, 4.95; N, 4.30; S, 9.58.
Synthesis of S-(4-Methylbenzyl)-2-aminooxyethanethiQj.
(8b) as illustrated in Figure 3 S-(4-methylbenzyl)-2-aminooxyethanethiol was synthesized by the method of Osby (Osby et al.
Tetrahedron Lett. 1984, 25, 2093-2096). The N-substituted phthalimide 12 (7.4 g, 23 mmol) was suspended in isopropanol (203 mL) and water (35 mL) to which was added NaBH4 (3.5 g, 92 mmol). The mixture was stirred at room temperature overnight. Acetic acid (25 mL) was slowly added till bubbling ceased, the flask stoppered and heated to 50 C for 2-3 hr. Volatiles were removed in vacuo, the resulting solution diluted with 1 N NaOH and extracted with EtOAc (4 x 50 mL). The combined EtOAc extractions were washed with saturated NaCl (1 x 50 mL) and dried over MgSO9. Volatiles were removed in vacuo and the resulting oil purified by flash chromatography (1:1 hexane:EtOAc) to yield 8b as a clear, colorless oil (3.2 g, 72%) 'H NMR (CDC13): 6 7.21 (d, 2H, J=8.0 Hz), 7.12 (d, 2H, J=8.0 Hz), 5.40 (br s, 2H, D20 ex.), 3.77 (t, 2H, J=6.5 Hz), 3.71 (s, 2H), 2.64 (t, 2H, J=6.5 Hz), 2.33 (s, 3H); FAB MS: calc for [C1oH1sNOS, H'] 198.0953, found 198.0958. Anal.
Calcd for C10H15NOS C, 60.88; H, 7.66; N, 7.10; S, 16.25.
Found C, 60.79; H, 7.88; N, 7.03; S, 16.11.
Claims (9)
1. A method for ligating a first oligopeptide with a second oligopeptide end to end for producing an oligopeptide product, the method comprising the following steps:
Step A: admixing the first and second oligopeptides in a reaction solution including a catalytic thiol, the first oligopeptide including a C-terminal residue having a C-terminal thioester, the second oligopeptide including an N-terminal residue having an N-terminal auxiliary functional group with an unoxidized sulfhydryl moiety, the N-terminal residue being non-glycine and non-cysteine if the C-terminal residue is glycine, the N-terminal residue being glycine if the C-terminal residue is non-glycine;
Step B: condensing the unoxidized sulfhydryl moiety of the N-terminal auxiliary functional group with the C-terminal thioester for producing an intermediate oligopeptide linking the first and second oligopeptides with an aminothioester bond; and then Step C: rearranging the aminothioester bond of the intermediate oligopeptide of said Step B for producing the oligopeptide product linking the first and second oligopeptides with an amide bond having a N-linked auxiliary functional group.
Step A: admixing the first and second oligopeptides in a reaction solution including a catalytic thiol, the first oligopeptide including a C-terminal residue having a C-terminal thioester, the second oligopeptide including an N-terminal residue having an N-terminal auxiliary functional group with an unoxidized sulfhydryl moiety, the N-terminal residue being non-glycine and non-cysteine if the C-terminal residue is glycine, the N-terminal residue being glycine if the C-terminal residue is non-glycine;
Step B: condensing the unoxidized sulfhydryl moiety of the N-terminal auxiliary functional group with the C-terminal thioester for producing an intermediate oligopeptide linking the first and second oligopeptides with an aminothioester bond; and then Step C: rearranging the aminothioester bond of the intermediate oligopeptide of said Step B for producing the oligopeptide product linking the first and second oligopeptides with an amide bond having a N-linked auxiliary functional group.
2. A method as described in claim 1 wherein, the catalytic thiol is selected from the group consisting of benzyl mercaptan and thiophenol.
3. A method as described in claim 2 wherein the N-terminal auxiliary functional group is N-.alpha.-(CH2)n-SH where
4. A method as described in claim 2 comprising the following additional step:
Step D: removing the N-terminal auxiliary functional group from the oligopeptide product of said Step C with a reducing agent for producing a native peptide bond.
Step D: removing the N-terminal auxiliary functional group from the oligopeptide product of said Step C with a reducing agent for producing a native peptide bond.
5. A method as described in claim 4 wherein the N-terminal auxiliary functional group is N-a-O-(CH2)n-SH
where 1<=n<=2.
where 1<=n<=2.
6. A method as described in claim 5 wherein the reducing agent is Zinc.
7. An oligopeptide intermediate comprising:
a first oligopeptide segment including a C-terminal residue having a C-terminal thioester, a second oligopeptide segment including a N-terminal residue having a N-terminal auxiliary functional group having an unoxidized sulfhydryl moiety, the N-terminal residue being non-glycine and non-cysteine if the C-terminal residue is glycine, the N-terminal residue being glycine if the C-terminal residue is non-glycine, and an aminothioester linkage unit linking the C-terminal thioester and the sulfhydryl moiety of the N-terminal auxiliary functional group, said aminothioester linkage unit spontaneously rearranging intramolecularly to form an amide bond linking said first and second oligopeptides segments end to end.
a first oligopeptide segment including a C-terminal residue having a C-terminal thioester, a second oligopeptide segment including a N-terminal residue having a N-terminal auxiliary functional group having an unoxidized sulfhydryl moiety, the N-terminal residue being non-glycine and non-cysteine if the C-terminal residue is glycine, the N-terminal residue being glycine if the C-terminal residue is non-glycine, and an aminothioester linkage unit linking the C-terminal thioester and the sulfhydryl moiety of the N-terminal auxiliary functional group, said aminothioester linkage unit spontaneously rearranging intramolecularly to form an amide bond linking said first and second oligopeptides segments end to end.
8. A peptide comprising a linkage unit represented by the formula: (aa1-CO)-S-(CH2)n-X-(N-aa2), wherein aa1-CO is a first amino acid having a carbonyl group, N-aa2 is a second amino acid having an amino group, wherein X is selected from the group consisting of oxygen and methylene, and wherein 1<=n<=2.
9. The peptide of claim 8 wherein either or both of aa1 and aa2 are glycine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1996/020610 WO1998028434A1 (en) | 1996-12-24 | 1996-12-24 | General chemical ligation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2273071A1 CA2273071A1 (en) | 1998-07-02 |
CA2273071C true CA2273071C (en) | 2008-07-29 |
Family
ID=22256350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002273071A Expired - Lifetime CA2273071C (en) | 1996-12-24 | 1996-12-24 | Method for ligating oligopeptides |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4358307B2 (en) |
CA (1) | CA2273071C (en) |
WO (1) | WO1998028434A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6307018B1 (en) * | 1996-12-24 | 2001-10-23 | The Scripps Research Institute | General chemical ligation |
EP1518862B1 (en) * | 1997-06-13 | 2007-02-21 | Gryphon Therapeutics, Inc. | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
JP2002505672A (en) | 1997-06-13 | 2002-02-19 | グライフォン サイエンシズ | Solid-phase natural chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution |
CA2301846A1 (en) | 1997-09-04 | 1999-03-11 | Gryphon Sciences | Modular protein libraries and methods of preparation |
WO2000012536A2 (en) | 1998-08-31 | 2000-03-09 | Gryphon Sciences | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides |
AUPP589598A0 (en) | 1998-09-14 | 1998-10-08 | University Of Queensland, The | Novel peptides |
US7482425B2 (en) | 1999-08-26 | 2009-01-27 | Amylin Pharmaceuticals, Inc. | Compositions for lipid matrix-assisted chemical ligation |
US6824981B2 (en) | 2000-08-11 | 2004-11-30 | Agilix Corporation | Ultra-sensitive detection systems using alterable peptide tags |
MXPA03001449A (en) * | 2000-09-01 | 2004-12-13 | Gryphon Therapeutics Inc | Nucleophile-stable thioester generating compounds, methods of production and use. |
BR0113623A (en) * | 2000-09-08 | 2004-06-22 | Gryphon Therapeutics Inc | Synthetic erythropoiesis stimulating proteins |
KR20030057529A (en) | 2000-09-08 | 2003-07-04 | 그리폰 테라퓨틱스, 인코포레이티드 | Synthetic erythropoiesis stimulating proteins |
GB0113657D0 (en) * | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
GB0123262D0 (en) * | 2001-09-27 | 2001-11-21 | Adprotech Ltd | Polymeric compounds |
AU2003303595A1 (en) | 2002-12-30 | 2004-07-29 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
DE10335584B4 (en) * | 2003-07-31 | 2006-06-29 | Philipps-Universität Marburg | Process for the preparation of cyclic molecules |
EP1770099A1 (en) | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
FR2952058B1 (en) * | 2009-10-29 | 2013-10-04 | Centre Nat Rech Scient | PROCESS FOR NATIVE LIGATION OF POLYPEPTIDES |
GB2482739A (en) * | 2010-08-13 | 2012-02-15 | Univ Reading | Processes and compounds useful in peptide synthesis |
FR2971509B1 (en) | 2011-02-16 | 2013-02-22 | Centre Nat Rech Scient | PROCESS FOR PREPARING PEPTIDES BY ASSEMBLING MULTIPLE PEPTIDE FRAGMENTS |
FR2981352B1 (en) | 2011-10-17 | 2015-07-03 | Centre Nat Rech Scient | PROCESS FOR PROTEIN SYNTHESIS |
FR2988392B1 (en) | 2012-03-21 | 2014-04-11 | Centre Nat Rech Scient | NATIVE LIGATION METHOD |
KR102544146B1 (en) * | 2017-03-02 | 2023-06-15 | 가부시키가이샤 도우사 고가쿠 겐큐쇼 | Manufacturing method of amino acid polymer |
CN107698474B (en) * | 2017-10-16 | 2019-10-22 | 中国科学技术大学 | Prosthetic linking arm, its synthesis method and the synthesis method of diubiquitin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5589356A (en) * | 1993-06-21 | 1996-12-31 | Vanderbilt University | Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement |
AU1560095A (en) * | 1994-01-06 | 1995-08-01 | Metabolix, Inc. | Methods for synthesizing oligomers containing hydroxy acid units |
-
1996
- 1996-12-24 CA CA002273071A patent/CA2273071C/en not_active Expired - Lifetime
- 1996-12-24 WO PCT/US1996/020610 patent/WO1998028434A1/en active Application Filing
- 1996-12-24 JP JP52871798A patent/JP4358307B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2001507027A (en) | 2001-05-29 |
WO1998028434A1 (en) | 1998-07-02 |
JP4358307B2 (en) | 2009-11-04 |
CA2273071A1 (en) | 1998-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2273071C (en) | Method for ligating oligopeptides | |
US6307018B1 (en) | General chemical ligation | |
JP4327589B2 (en) | Improved natural chemical ligation using three or more components | |
US7030217B2 (en) | Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution | |
Aimoto | Contemporary methods for peptide and protein synthesis | |
US7435791B2 (en) | Process for rapid solution synthesis of peptides | |
US7884182B2 (en) | Chemical peptide ligation with three or more components | |
US7566697B2 (en) | Carboxy protection strategies for acidic C-terminal amino acids in chemical ligation of oligopeptides | |
US6277957B1 (en) | Method for production of acylthio derivatives | |
EP1518862B1 (en) | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution | |
WO2004050686A2 (en) | Process and supports for synthesis of peptides comprising a thioester or thioacid | |
津田修吾 et al. | Development of synthetic procedures using novel thioester derivatives for chemical synthesis of proteins | |
KR19990035976A (en) | Process for preparing α- (N, N-dialkyl) -amino carboxylic acid amide | |
Baas et al. | New approaches for native chemical ligation | |
Maynard | Preparation of peptide thioacids | |
AU2002319850A1 (en) | Improved native chemical ligation with three or more components | |
BRPI0706400B1 (en) | SELECTIVE ENZYMATIC HYDROLYSIS OF TERC-BUTIL C-TERMINAL ESTERS OF PEPTIDE SUBSTRATES, FOR THE CONVERGENT SYNTHESIS OF A PEPTIDE OF TWO OR MORE PEPTIDE FRAGMENTS | |
NZ520267A (en) | Process for rapid solution synthesis of peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20161228 |